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ABSTRACT 
 
CC-Chemokine receptor like 2 (CCRL2) is the newest member of the atypical chemokine receptor family, 
a set of proteins which tend to act as “decoy receptors”, causing a chemoattractant gradient of their 
ligands.  Using SYBR-Green and Taqman RT-PCR analysis of murine tissue, this study aimed to 
characterise the expression of CCRL2 in the spleen, thymus and lymph nodes.  Using specifically 
designed primers, the PCR techniques detected an alternative, “long”, spliced variant of CCRL2 within 
the thymus.  CCRL2 mRNA expression was also defined over 8 days, during the lifetime of the germinal 
centre. CCRL2 mRNA expression was measured within B cells, the germinal centre or the T Zone.  Due to 
its high expression within plasma B cells at days 4 and 7, CCRL2 may be involved in plasma cell exit from 
the GC.  However, CCRL2 mRNA was also expressed within the germinal centre on days 7 and 8, which 
may suggest the receptor also has a role in germinal centre breakdown.  Finally, this study also started 
the process of monoclonal antibody production to murine CCRL2.  CCRL2 DNA was successfully cloned 
into a plasmid vector and transformed into E. coli in preparation for transfection into a mammalian cell 
line. 
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ABBREVIATIONS 
 
ACR Atypical Chemokine Receptor 
β2M β2-Microglobulin 
BCR B-Cell Receptor 
BLN Brachial Lymph Node 
CCRL2 CC-Chemokine Receptor Like 2 
CRAM Chemokine Receptor on Activated Macrophages 
Ct Cycle Number of PCR threshold 
DARC Duffy Antigen Receptor for Chemokines 
DZ Dark Zone of the Germinal Centre 
GC Germinal Centre 
GPCR G-protein Coupled Receptor 
H+ CCRL2 cDNA amplified with HindIII forward primer 
H- PCR amplification with HindIII forward primer but without CCRL2 cDNA template 
HA+ CCRL2 cDNA amplified with HindIII-ATG forward primer 
HA- PCR amplification with HindIII-ATG forward primer but without CCRL2 cDNA template 
HPRT Hypoxanthine-guanine phosphoribosyltransferase 
ILN Inguinal Lymph Node 
LN Lymph Node 
LZ Light Zone of the Germinal Centre 
MLN Mesenteric Lymph Node 
QM Quasi-Monoclonal 
RT-PCR Real Time Polymerase Chain Reaction 
TD T-cell Dependent Response 
TI T-cell Independent Response 
TZ T-cell Zone 
SDS-PAGE Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
Tmelt Melting temperature of DNA 
U/C Uncut plasmid vector 
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1. INTRODUCTION 
 
The spleen is a secondary lymphoid organ located in the abdomen, connected to the stomach and 
located directly below the diaphragm (1).  It has a very distinct architecture, where different cells are 
split into distinct areas within either red or white pulp (reviewed by Mebius and Kraal (1)).  The red pulp 
has the capacity to filter the blood and remove old erythrocytes and recycle iron (1).  The white pulp, 
however, is a zone of clonal expansion of activated B cells, with a structure similar to that of the lymph 
node (1).  This study focuses on the white pulp area. 
 
1.1 The White Pulp 
The lymphoid area of the spleen is the white pulp, where T and B cells are located in specific 
compartments, which allows for B cell hypermutation and differentiation.  A central arteriole is 
surrounded by the T cell zone (TZ), also known as periarteriolar lymphoid sheath (PALS).  Next to the TZ 
are the follicles (which house the majority of naive B cells) and is surrounded by the marginal zone (MZ).  
The marginal sinus is the site of entry for lymphocytes, macrophages and dendritic cells, and this is the 
area which separates the red and white pulp (2).  Although similar, the precise architecture of the white 
pulp differs between human and mouse, particularly in the marginal zone (1, 3) (figure 1.1). 
As stated, the white pulp is a compartment which allows for B cell hypermutation and differentiation.   
Although B cells can be presented antigen by T cells, they can also respond directly to antigen as long as 
it is able to cross-link the B cell receptor (BCR) (2).   
 
1.2 T-cell dependent and T-cell independent responses 
A T-cell dependent response (TD) is an antibody response by B cells which is induced by protein 
antigens.  Antigen is taken up by B cells which present it to T cells; recognition of the same antigen by 
both B and T cells allows reciprocal activation of each other (2).  Subsequent costimulation of the T cells 
permits it to induce somatic hypermutation and class switching within the B cells (2), leading to the 
formation of germinal centres. 
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Figure 1.1. Comparison of the splenic white pulp of a) mouse and b) human.  Main differences include 
the structure of the marginal zone, which in human is split into inner and outer sections.  Picture adapted 
from Mebius and Kraal (1)   
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Conversely, a T-cell independent response (TI) does not require the collaboration of T and B cells.  This is 
typical for non-peptide antigens such as DNA, polysaccharides and phospholipids which do not activate 
T cells (4).  TI responses can be split into two types; TI-I in which the antigen react with Toll-like 
receptors on the B cells surface causing activation, and TI-II, where the antigen is able to cross link 
multiple BCRs on the B cell surface (4). Both naive and experienced memory B cells participate in TI 
responses (figure 1.2) however, the memory B cells have a much enhanced response to TI stimulation 
(4).  TI responses can also lead to class switching (2) and so the formation of a GC.   
 
1.2.1 The Germinal Centre 
The Germinal Centre (GC) is defined by MacLennan as a structure which “develops in the B-cell follicles 
of secondary lymphoid tissues during TD responses, where B cells undergo massive clonal expansion and 
activate a site-directed hypermutation mechanism on Ig-variable region genes” (5).  These GCs are made 
up of distinct areas and zones which aid this process (figure 1.3).  The dark zone (DZ) contains large B 
cells known as centroblasts, which rapidly proliferate (on every 6-8 hours), however only 2 or 3 B cells 
per GC generate expanded clones (4).  While proliferating, the B cells undergo somatic hypermutation of 
the variable region of their antibody genes (4, 6).  Somatic hypermutation is within the variable domains 
of the immunoglobulin, occurring via single nucleotide changes or microdeletions (7) and causing either 
enhanced or reduced affinity for the receptor to antigen. 
Within the light zone (LZ) are smaller, nonproliferating centrocytes which are derived from the larger 
centroblasts (6). These smaller cells compete for binding of antigen present by follicular dendritic cells 
(6), with high affinity receptors out-competing low affinity ones and thus enabling cell survival.  The 
remaining B cells die via apoptosis due to lack of stimulation from the B cell receptor-antigen complex 
(2).  Two-photon laser-scanning microscopy has shown that B cells are able to move from the DZ to the 
LZ and back again (8), however these results are regarded by many as controversial.  Successfully 
selected B cells can differentiate into plasma or memory cells in the LZ (2).  To ensure an antibody 
response occurs early after pathogen infection, B cells can leave the GC after a small number of 
proliferation cycles, however others can remain in the GC for 2 weeks (4). 
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Figure 1.2 T-cell independent and T-cell dependent antibody responses.  Adapted from Zubler (4) 
Key:  Bn - naive B cells; Bm – memory B cells; DC - dendritic cells; FDC - follicular dendritic cells; GC - 
germinal centre; MZ - marginal zone; PL - plasma cells;  TH - T helper cells. 
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Figure 1.3.  Structure of the germinal centre; a) architecture of the GC within a B cell follicle.  
Proliferating centroblasts are within the dark zone, nonproliferating centrocytes in the light zone; b) 
immunostaining of a mouse spleen staining for IgD and CD35 (9) 
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1.3 An Overview of Chemokine Receptors 
Chemokines (“chemotactic cytokines”) are a superfamily of 8-10kDa glycoproteins which allow for 
various functions including angiogenesis, organogenesis and hematopoiesis.  Chemokines are defined 
via a set of 4 conserved cysteine residues linked by disulphide bonds (10).  The two major subfamilies of 
chemokines are named CC or CXC, depending on whether the two first cysteines are adjacent or 
separated by another amino acid (10).  Other chemokines include CX3CL1, XCL1 and XCL2 (11).   
Chemokines bind to G protein coupled receptors (GPCRs) on the cell surface to produce their effect on 
the target cell.    GPCRs in the human genome form five main families (12), and the chemokine receptors 
are found within the Rhodopsin family.  GPCRs are “serpentine” receptors, with 7 transmembrane 
helices connected by loops.  The second intracellular loop is of particular interest: if this loop is missing 
the canonical motif DRYLAIV, the receptor is unable to couple to a G protein.  Such chemokine receptors 
with this unusual property are called “atypical chemokine receptors” (ACRs). 
It is known that GPCRs can transduce signals and cause a response in the absence of G proteins 
(reviewed by Sun et al (2007) (13)), disputing the initial ideas that ACRs are “silent”.  One such response 
is the internalisation of the chemokine ligand, which ACRs can do so efficiently they are also known as 
“interceptors” (internalising receptors).  Consequences of interceptor actions have been different under 
specific conditions, including acting as a scavenger in competition with typical chemokine receptors and 
degradation of internalised chemokine (14).   
Currently there are 5 members of the ACR family, DARC (Duffy Antigen Receptor for Chemokines); D6; 
CXCR7; CC-Chemokine Receptor Like 1 and CC-Chemokine Receptor Like 2 (CCRL1 and CCRL2 
respectively) (15).  This study focuses on the latter of these receptors. 
1.4  CCRL2 
L-CCR (LPS-inducible CC chemokine receptor related gene) (16), HCR (human chemokine receptor) or 
CRAM (chemokine receptor on activated macrophages) are all alternative names for CCRL2 (16-18), the 
newest member of the ACR family.  CCRL2 has the highest degree of homology with CCR1, an 
inflammatory chemokine receptor (19).  Two alternative splice variants of the receptor are known 
(designated CRAM-A and CRAM-B), with different N termini (18).  CCRL2 has been shown to be 
expressed on almost all human hematopoietic cells (20) however it was not initially detected in B cells 
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(21).  A subsequent study reported that CRAM was expressed by B cells depending on the maturation 
stage of that cell (22). 
As of yet, a definitive ligand for mouse CCRL2 has been described in full (figure 1.4).  In 2003 Biber and 
colleagues investigated chemotaxis of CCRL2 expressing HEK 293 cells when stimulated with various 
chemokines (23).  This suggested that CCL2, CCL5, CCL7 and CCL8 induced chemotaxis, with CCL5 having 
the greatest effect (23).  However, the same result was not shown in CHO cell CCRL2 transfectants 
within the same study (23) and also not shown in a second chemotaxis study by a different group who 
used L1.2 cell transfectants (24).  A more recent study by Leick et al. researched ligands for human 
CRAM and determined that the chemokine CCL19 can bind with an affinity similar to that which it binds 
another receptor, CCR7 (25). 
1.5 The Role of Chemokines in the Germinal Centre
Chemokines play a crucial role in the formation and maintenance of the GC.  For example, before the GC 
has formed, CXCL13 expressed within the follicle is required for B cell migration to this area, the 
receptor CXCR5 mediating this migration (26).  Conversely, CCL19 and CCL21 expressed within the PALS 
attract CCR7 expressing T cells and dendritic cells to the T-zone (27).  The chemokine receptor CXCR5 is 
required for direction of cells to the LZ, and without CXCR4, B cells are excluded from the DZ (28). 
1.5.1 CCRL2 within the Germinal Centre 
Although a role for CCRL2 has yet to be established within the GC, two sets of evidence point to 
functional role of this chemokine receptor.  First, Otero and colleagues showed that CCRL2 knockout 
mice had normal recruitment of DCs to the lung, however this was defective in antigen loaded DCs to 
mediastinal LNs (19).  Second, CCRL2 has been shown to be present within the B cell follicle of the 
human LN using fluorescent staining (figure 1.5). 
1.6 Aims of project 
 
 To characterise the expression of CCRL2 within the spleen, lymph node and thymus of mouse 
 To determine the expression of CCRL2 in B cells over the days of a germinal centre reaction 
 To clone CCRL2 into a plasmid vector for the first stages of monoclonal antibody production 
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Figure 1.4 Chemokine receptors which bind the potential ligands of CCRL2; CCL5 and CCL19. 
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Figure 1.5 Human lymph node B cell follicle stained for CCRL2 (red) and DAPI (gray).  Image provided by 
Poonam Kelay and Antal Rot, University of Birmingham. 
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2.  MATERIALS AND METHODS 
 
2.1 Mice for T-independent response 
Mouse work was carried out by others and is shortly summarised here.  QM B18κeYFP mice were 
sacrificed, spleens removed and B cells sorted.  C57BL6 mice were injected with these B cells and one 
day later immunised with NP-Ficoll.  After immunisation mice were sacrificed after 0, 1, 3, 4 or 7 days.  
Spleens were removed and B cells were sorted by FACS into eYFP+, eYFP- or further into eYFP+CD138- 
(donor germinal centre B cells), eYFP+CD138+ (donor plasma B cells) and eYFP-CD138- (host B cells). 
2.2 Mice for T-dependent immune response 
C57BL6 mice were primed with chicken gamma globulin (CGG) and after 5 weeks injected with NP-CGG 
and anti-NP IgM.  Mouse was sacrificed on day 8 and spleen extracted. 
2.3  cDNA Preparation 
2.3.1 mRNA extraction.   
Tissue sections or sorted cell samples were stored at -80°C until needed.  Samples were disrupted using 
the QIAshredder columns (Qiagen, Crawley, UK) or via mechanical homogenisation and extraction of 
mRNA was conducted using the RNeasy Mini kit (tissue samples and sorted cells >20,000 in number) or 
RNeasy Micro kit (sorted cells <20,000 in number) (Qiagen) as per the manufacturer’s instructions.  RNA 
was eluted in 30µl of RNAse free water and stored at -80°C until required. 
2.3.2 cDNA preparation 
cDNA was prepared by one of two methods.  Either the 30µl RNA sample was mixed with 3µl random 
primer (Promega Biosciences, CA, USA) and denatured at 70°C for 10mins.  This was shock cooled on ice 
and 27µl of reverse transcription mix was added (table 2.1).  The sample was incubated for 1hr at 41°C 
and subsequently at 90°C for 10mins.  In the second method the sample was diluted to 833ng of RNA in 
a 14µl solution and to this 6µl of Superscript VILO reverse transcription mix was added (Invitrogen, 
Paisley, Scotland; table 2.1).  Sample was heated to 25°C for 10 mins, 42°C for 60mins and subsequently 
85°C for 5mins. Prepared cDNA was stored at -20°C until needed. 
2.4 Laser capture microdissection 
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6µm spleen sections from mouse in 2.2 were cut using a cryostat (Bright Instruments, Huntington, UK) 
and picked onto PALM Membrane Slides NF (PALM Microlaser Technologies, Bernried, Germany) and 
adjacent sections were cut onto teflon framed glass slides.  All were fixed in acetone at 4°C for 20mins.  
PALM slides were stained in 1% cresyl violet for 2.5mins, were washed sequentially in 50%, 70% and 
100% ethanol and subsequently air dried. 
Stained glass slides were used as a reference for sections to be cut from the PALM Membrane Slides NF.  
Laser capture microdissection was performed using a Microbeam HT microscope (PALM Microlaser 
Technologies) and Palm@Robo software version 3.0.  Microdissected areas were captured into 20µl RLT 
buffer (Qiagen) and cDNA prepared as previously described (section 2.1) 
2.5 Taqman Semiquantitative Real Time PCR 
1µl of cDNA preparation added to a well of a 384 well plate along with relevant primers and probes 
(appendix A) with 1x Taqman Universal PCR Master Mix (all Applied Biosystems, CA, USA).  The plate is 
covered with clear adhesive foil (Applied Biosystems), vortexed and centrifuged (short spin up to 
2000rpm).  Wells contained primers specific for both target gene and housekeeping gene (β2-
microglobulin, [β2M]) according to previous optimisation experiments.  Plate was loaded into an ABI 
7900 Real-time PCR machine (Applied Biosystems) with a temperature cycle as shown in table 2.2.  
Fluorescence analysis was performed by SDS 2.2.2 software (Applied Biosystems) with a threshold set 
manually during the logarithmic phase of the PCR.  The cycle where signal above threshold was obtained 
(Ct) was recorded for each sample, and relative quantity of target gene expressed deduced by taking ΔCt 
(Ct-sample minus Ct-housekeeping) and calculating 2-ΔCt.  A one-tailed Mann-Whitney U Test was 
performed to test statistical significance. 
2.6 SYBR Green Real Time PCR 
13.5µl SYBR Green PCR reaction mix (table 2.1) was added to each well, made up of either forward and 
reverse primers for CCRL2 or the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase 
(HPRT).  RNA extracted from thymus, spleen and lymph node by others had cDNA prepared as 
described.  This was diluted 5x and 11.5µl added to the wells.  Plate was loaded into Stratagene 
Mx3000P machine (Agilent Technologies, Edinburgh, UK) with the cycle shown in table 2.2.  
Fluorescence analysis was performed using MxPro Software. 
2.7 Western Blot 
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2.7.1 Protein preparation from tissue 
Thymus, spleen, mesenteric lymph node (MLN) and inguinal lymph node (ILN) extracted from 8 week 
C57BL6 mouse and frozen in liquid nitrogen until needed.  Tissues were dissected and appropriate 
amounts of RIPA lysis buffer were added depending on the mass of the tissue (300µl lysis buffer for 
every 5mg tissue).  Tissues were homogenised and left on a shaker at 4°C for 2 hours.  Samples were 
centrifuged at 4°C for 20mins at 12000 rpm and kept at -80°C until needed. 
2.7.2 Protein concentration determination 
Protein concentration of each sample was determined using Pierce BCA Protein Assay Kit (Thermo 
Scientific, MA, USA) as per the manufacturer’s instructions. 
2.7.3 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Separation gel was made up to a 15% acrylamide.  Markers used were Pageruler Plus Protein Ladder 
(Fermentas Life Sceinces, St. Leon-Rot, Germany).  11µg total protein was loaded. 
2.7.4 Western Blot 
Proteins transferred from gel to membrane and membrane blocked overnight with 5% milk PBS-
0.1%Tween (PBST).  Incubated 1hr in mouse anti-β-actin antibody or polyclonal rabbit anti-mouse CCRL2 
antibody (Sigma-Aldrich, Poole, UK) in 5% milk PBST and subsequently washed three times for 15mins in 
PBST.  Further incubation for 1hr in biotinylated-goat anti-mouse-IgG (Invitrogen) or anti-rabbit IgG-
biotin (Sigma-Aldrich) in 5% milk PBST and washed as before.  Final incubation of 1hr with strepavidin 
peroxidise (Sigma-Aldrich) in 5% milk PBST before five 5min PBST washes.  Blots developed with 
Chemiluminescent peroxidase substrate (Sigma-Aldrich). 
2.8 Fluorescence staining of spleen sections 
Spleen sections were cut by others onto glass slides using a cryostat to a thickness of 6µm.  Sections 
were blocked for 15min with 10% goat serum before being stained with polyclonal rabbit anti-mouse 
CCRL2 antibody (Sigma-Aldrich) for 1 hour.  Slides were washed in PBS before application of polyclonal 
goat anti-rabbit-biotinylated (Dako, Ely, UK) secondary antibody for 30 mins.  After another wash step 
slides were incubated with streptavidin-555 (Invitrogen) in the dark for 20mins.  A further wash step was 
conducted before the slides were stained with DAPI and washed 3 times.  1 drop of Vectashield 
Mounting Medium (Vector Laboratories, Peterborough, UK) was added to each spleen section before 
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coverslip added and sealed using clear nail varnish.  Slides were viewed using a Leica Microscope 
DM6000. 
2.9 Production of plasmid vector containing CCRL2 DNA 
2.9.1 Transformation of E. coli  
2.9.1.1 Amplification of CCRL2 DNA 
A commericially available vector carrying myc-dkk c-terminal tagged CCRL2 cDNA (Origene, MD, USA) 
was used as a template for CCRL2 amplification.  The reaction was designed to remove the tags and add 
a stop codon as well as restriction enzyme sites to enable further cloning.  Two sets of alternative 
forward primers were used that amplified from the ATG start codon or included an upstream sequence 
containing a ribosomal binding site with Kozac sequence (table 2.1 and PCR program in table 2.2). 
2.9.1.2 Ligation of CCRL2 DNA with plasmid vector 
Amplified DNA plus negative controls were separated on a 1% agarose gel with SYBR Safe, all 
subsequent agarose gels used this method.  The agarose with DNA of expected product size (1150bp) 
were cut from the gel and purified using GeneJET Gel Extraction Set (Fermentas Life Sciences) as per the 
manufacturer’s instructions.  Further visualisation of the gel ensured that all DNA extracted.  DNA 
concentration was determined using a Nandrop 1000 Spectrophotometer (Thermo Scientific).  The 
vector pLNCX2 (ClonTech, USA, Appendix B) and amplified CCRL2 DNA were incubated with SalI and 
HindIII restriction enzymes in 2x Tango buffer, as recommended by Double Digest application 
(Fermentas Life Sciences) or incubated with HindIII and SalI enzymes separately.  The DNA was purified 
using a PCR purification kit (Fermentas Life Sciences) as per the manufacturer’s instructions.  The 
restriction digest was evaluated using agarose gel.  The vector pLNCX2 was incubated with either the cut 
HindIII or HindIII-ATG amplified CCRL2 DNA with the LigaFast Rapid DNA Ligation System (Promega 
Biosciences), as per the manufacturer’s instructions.   
2.9.1.3 Transformation of E. coli with vector containing CCRL2 DNA 
50µl aliquots of α-select chemically competent cells (Bioline) were stored at -80°C until required, and 
were thawed on wet ice.  5µl of ligated vector was added to the cells were and incubated on ice for 
30mins.  The bacteria were transformed by heat-shock at 42°C for 30-45s and subsequently incubated 
on ice for 2mins.  945µl of SOC media was added and tubes incubated for 1hr at 200rpm at 37°C.  The 
transformed bacteria were plated on agar with carbenicillin (Bioline, London, UK) and incubated 
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overnight at 37°C.  Individual colonies were thereafter grown in LB broth with carbencillin on shaker 
overnight at 37°C.   
2.9.2. Determination of positive plasmid clones 
Overnight bacterial colonies were used for vector purification using GeneJET Plasmid MiniPrep 
(Fermentas Life Sciences) as per the manufacturer’s instructions and incubated overnight with SalI and 
XhoI restriction enzymes in Buffer O, as recommended by Double Digest application (Fermentas Life 
Sciences).  Samples analysed using agarose gel.  Positive clones were sequenced at The University of 
Birmingham Biosciences Department using forward and reverse primers for the vector (appendix B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
 
 
Table 2.1  Reaction Mixtures and buffers. 
 
Reverse Transcription Mix 
SuperScript VILO 
Reverse 
Transcription Mix 
SYBR Green PCR Mix 
CCRL2 Amplification 
Reaction Mix 
12µl 5x first strand buffer 
(Invitrogen) 
2µl 10X SuperScript 
Enzyme Mix 
12.5µl SensiMix 2 times  0.4µl 10mM dNTP 
6µl DTT 0.1M (Invitrogen) 
4µl 5X VILO 
Reaction Mix  
0.5µl SYBR Green  
4µl 5X Phusion HF 
Buffer (New England 
Biolabs) 
3µl dNTP (10mM) 
(Invitrogen) 
 
0.25µl 20µM CCRL2 
Forward primer  
0.5µl 20µM CCRL2 
forward primer 
3µl Moloney murine 
leukemia virus reverse 
transcriptase (Invitrogen) 
0.25µl 20µM CCRL2 
Reverse primer  
0.5µl 20µM CCRL2 
reverse primer 
1.5µl RNasin RNase inhibitor 
(Promega) 
 
13.4µl water 
1.5µl RNase free water 
0.2µl Phusion DNA 
polymerase (New 
England Biolabs) 
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Table 2.2.  PCR cycling programmes. 
 
Semiquantitative Real-time 
PCR 
SYBR Green PCR CCRL2 Amplification PCR 
50°C for 2mins 95°C for 10min 98°C for 30s 
95°C for 10mins 95°C for 20s 
For 40 cycles 
98°C for 10s For 37 
cycles 95°C for 15s 
For 40 cycles 
65°C for 20s 72°C for 45s 
60°C for 1min 72°C for 30s 72°C for 2mins 
 Tmelt curve addition 4°C until DNA needed 
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3. RESULTS 
 
3.1 Presence of an alternative splice variant of CCRL2 in the thymus. 
3.1.1 SYBR Green Real Time PCR analysis of thymus, spleen and inguinal lymph node sections 
Previous work within the group had suggested that CCRL2 mRNA is spliced differently in the thymus – 
indicating the possible existence of a longer form of the protein. These previous findings were 
supported in this study using SYBR Green PCR and analysing the dissociation curve of CCRL2 cDNA 
prepared from mouse thymus, spleen and ILN (figure 3.1).  Both the spleen and ILN sections had a 
melting temperature (Tmelt) of 82°C.  However, even though the thymus had a minor peak in 
fluorescence at 82°C, the major fluorescence was seen at 85°C. 
3.1.2 Taqman real-time PCR of thymus, spleen and lymph node sections 
3.1.2.1 Optimisation of Taqman real-time PCR CCRL2 long and short primers 
To further determine differences in long and short forms of the CCRL2 transcript, primers and probes 
were designed for use in Taqman real-time PCR applications (appendix A).   Optimisation of reaction 
conditions for these CCRL2 long and short primers and probes occurred in three stages.  First, the 
optimal primer concentration was deduced, using a checkerboard titration with forward and reverse 
primers in 900nM, 300nM and 50nM concentrations.  The probe concentration was kept constant.  For 
both the long and short CCRL2 primers, 900nM/900nM was found to be the optimal concentration for 
both the forward and reverse primers (ie concentration at which the Ct was consistently at its lowest 
value (figure 3.2). 
Second, the optimal probe concentration was determined, where probe was diluted from 225 to 25nM 
in solutions containing forward and reverse primers at 900nM (deduced optimal concentration).  Both  
the long and short primer probes gave the lowest Ct at 200nM (figure 3.3).   
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Figure 3.1.   SYBR Green RT-PCR dissociation curve for thymus, spleen and inguinal lymph node.  cDNA amplified 
using CCRL2 primers.  Primers for experiment are listed in Appendix A.   
Key (duplicates):  
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Figure 3.2.  First stage of Taqman real-time primer optimisation - determination of optimal primer 
concentration.  a) Ct against primer concentration for CCRL2 short form primer; b) Ct against primer 
concentration for CCRL2 long form primer.  Optimal concentration of primers is that which gives the 
lower Ct at the lowest primer concentration 
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Figure 3.3.  Optimisation of CCRL2 a) short and b) long FAM probe.  Both show Ct against increasing 
probe concentration.  Probe was diluted but cDNA template and primer concentration stayed constant.  
Optimal probe concentration is the lowest concentration which gives the gives lowest Ct value. 
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Finally, the primers were analysed for their ability to be used in a multiplex reaction with the 
housekeeping gene β2M.  Serial dilutions of the cDNA template were analysed with only CCRL2 primers, 
only β2M primers or both together, and the relationship between dilution and Ct compared for each 
(figure 3.4).  The short form of the primer shows that upon dilution, the Ct value for both β2M and 
CCRL2 remains similar (figure 3.4a), indicating that it is capable of being used in a multiplex reaction 
with the housekeeping gene.  Conversely, although at higher dilutions the long form gives similar Ct 
values for both the target and housekeeping genes (figure 3.4b), at smaller dilutions it does not give any 
signal when used in multiplex.  Therefore, although it could be possible to use the two primers in 
multiplex, to reduce risk within this study only singleplex reactions are used. 
3.1.2.2 Detection of long and short forms of CCRL2 in thymus, spleen and lymph node sections using 
Taqman RT-PCR 
cDNA was prepared from the sections of thymus, spleen, ILN (n=3), Brachial Lymph Node (BLN) and MLN 
(n=2) of 8 week wild type BL6 mice.  1µl of cDNA was loaded into a 384-well plate along with optimised 
CCRL2 short (multiplexed with β2-M) or optimised CCRL2 long (singleplex) primers and RT-PCR was 
performed.  To ensure the results were not due to the nature of the housekeeping gene used, both 
short and long isoforms were compared to the expression of β-actin mRNA.  Figure 3.5 shows that with 
both housekeeping genes, all tissues produced a signal with CCRL2 short primers.  In this study, long 
form CCRL2 was amplified not only from the thymus, but also from spleen and ILN samples.  However, 
the median levels of expression of the long form of CCRL2 mRNA in spleen and ILN are at least 10x lower 
than expression within the thymus. 
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Figure 3.4.  β2-Microglobulin and CCRL2 a) short and b) long primers amplification either in 
singleplex or in multuiplex.   The cDNA template is diluted and primers and probes are used in 
singleplex and multiplex reactions at their optimal concentrations to determine if the presence of the 
housekeeping primers changes the efficiency of amplification. 
Key:  
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Figure 3.5.  RT-PCR of spleen, thymus, ILN, BLN and MLN sections with CCRL2 long or short form 
primers.  Relative expression of both forms of the protein with housekeeping gene a) β2-M and b) β-
actin.   
Key:  
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3.1.3 Western Blot analysis using polyclonal rabbit anti-mouse CCRL2 antibody 
Thymus, spleen, MLN and ILN were extracted from an 8 week old C57BL6 mouse and homogenised to 
enable the release of protein.  ELISA analysis using a BCA protein assay kit enabled the determination of 
the protein concentration of each tissue (figure 3.6, table 3.1) to ensure optimal amounts of sample 
protein (5-20µg) was loaded onto the SDS-PAGE.  Concentration determination likely to be accurate as 
curve fits to points to an R2 of 0.988. 
Western blot analysis was performed using β-actin primary antibody (figure 3.7a) and polyclonal anti-
CCRL2 primary antibody (figure 3.7b).  All four tissues had the housekeeping protein present at the 
expected protein size, however CCRL2 was present between 250kDa and 70kDa, not at the expected size 
of 41kDa.  Also, no CCRL2 was detectable within the ILN protein preparation.  It also appears that within 
the MLN section there are two bands of CCRL2 present, which is also possible in the thymus and spleen 
sections, however the blot is too overexposed to confirm this.  CCRL2 negative tissue from CCRL2 
knockout mice can be used to test possible cross-reactivity of the antibody with unrelated antigens. 
3.2 The role of CCRL2 within cells of the Germinal Centre 
3.2.1 Expression of chemokine receptors in sorted B cells from a T-cell independent response. 
B cells from NP-specific QM mice (29) were transferred to mice which were subsequently immunised 
with the TI antigen NP-Ficoll.  This causes B cell expansion and development of plasma and germinal 
centre B cells around day 3 and 4.  Most TI germinal centres start to involute at day 5 due to missing T 
cell help (30).  B cells were sorted at different time points, cDNA was prepared and a Taqman RT-PCR 
was performed as described.   All experiments were conducted in a singleplex reaction except for the 
short form of CCRL2 and the chemokine receptors CCR2 and CCR5, which were all used in multiplex with 
β2M. 
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Table 3.1.  Protein concentration of thymus, spleen, mesenteric LN and inguinal LN sections as 
determined from ELISA standard curve. 
Tissue 
Average Absorbance at 
562nm  - Blank 
Protein Concentration 
(µg/ml) 
Spleen 0.827 1453.92 
Thymus 0.594 922.40 
MLN 0.590 915.23 
ILN 0.399 559.33 
 
 
 
 
 
 
 
 
Figure 3.6.  Standard curve from ELISA analysis of protein concentration from standards provided in 
the BCA protein assay kit.  Protein concentration from samples determined from quadratic equation 
stated. 
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Figure 3.7.  Western blot analysis of ILN, MLN, thymus and spleen for a) β-actin and b) CCRL2.  
Expected mass of β-actin is 42kDa and that of CCRL2 is 41kDa. 
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CXCR5 is a chemokine receptor that is important for follicular organisation, and it has also been 
associated with germinal centre organisation (28).  Figure 3.8 shows the expression of CXCR5 mRNA in 
sorted cells.  On days 3 and 4 post NP-Ficoll immunisation, the expression of this receptor on activated B 
cells is significantly reduced compared to that on the non-activated host B cells (p=0.01).  Upon reaching 
day 7 CXCR5 levels in GC cells have become similar to unstimulated follicular host B cells, while it is 
undetectable in plasma cells (p=0.03). 
To determine whether CCRL2 has a role during B cell differentiation its expression was detected using 
RT-PCR (figure 3.9).  CCRL2 is present in baseline levels on unactivated cells on day 0 and day 3.  Four 
days after immunisation CCRL2 mRNA is present on plasma B cells, while on GC B cells it is expressed at 
baseline levels (p=0.01), with plasma cells having approximately 10x more expression of CCRL2 mRNA.  
By day 7, there is no difference in CCRL2 expression on plasma cells, however, GC B cells at this stage 
now also express the mRNA at a level similar to that of plasma B cells.  However, the difference between 
days 4 and 7 GC B cells is insignificant (p=0.1), even though the figure would suggest otherwise.  The 
likely cause of would probably the single anomalous result where the mRNA expression of CCRL2 10x 
lower than of the other GC B cell samples.  
 On day 7 non-activated host B cells seem to express lower levels of CCRL2 mRNA than the transferred B 
cells.  This difference, however, was insignificant.  It is possible that this is due to a mix up in 2 samples 
from one of the four mice used in this experiment (figure 3.9), indicating that the experiment should be 
repeated. 
CCRL2 long form primer was also tested on all these samples and was undetectable in each sample (data 
not shown). 
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Figure 3.8.  Expression of chemokine receptor CXCR5 in B cells sorted on different days after a T-cell independent 
immune response.    * p= 0.03; ** p= 0.01 
Key: 
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Figure 3.9.  Relative expression of CCRL2 short form in B cells sorted on different days after a T-cell independent 
immune response. *p=0.01 
Key:  
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Figures 3.10 and 3.11 show the expression mRNA coding for other chemokine receptors on the sorted B 
cell population, particularly those which potentially share ligands with CCRL2 (figure 1.4).  CCR7 binds 
the chemokine CCL19, and its mRNA expression is shown in figure 3.10.  It shows that CCR7 is expressed 
on non-activated B cells.  mRNA expression on activated GC cells is also high.  However, at day 7 a vast 
difference (100x less) of CCR7 mRNA is shown within plasma cells (p=0.02).  It should also be noted that 
this is the only chemokine receptor studied where expression on the mRNA level appears to be higher 
than that of the housekeeping gene. 
The final three chemokine receptors to be studied were CCR1, CCR4 and CCR5 (figure 3.11).  These three 
receptors all bind CCL5, another potential ligand for CCRL2 (figure 1.4).  All of these chemokine 
receptors show an increased expression in early GC B cells (day 3 and day 4).  Interestingly, host cells 
showed an increase in this chemokine receptor at the same time.  On day 7, all sorted cell populations 
had lost expression of all 3 chemokine receptors. 
3.2.2 Attempt to stain for CCRL2 expression in whole spleen sections  
Although the antibody ordered from Sigma-Aldrich was tested by the company on spleen sections in a 
Western blot analysis, it had not been previously tested for tissue staining.  For this purpose, the 
antibody was used to stain 6µm spleen sections of day 7 TI response, where CCRL2 shown to be 
expressed in plasma and germinal centre B cells from RT-PCR data.  A negative control was also used, 
where there was no primary antibody present (figure 3.12a).  Fluorescence was greater in the section 
with anti-CCRL2 antibody (figure 3.12b) showing that the staining is due to primary antibody.  However, 
the staining does not localised to B cells.  Staining of CCRL2 negative tissue from CCRL2 knockout mice 
will deduce if this staining is specific for CCRL2, or due to cross reactivity with other antigens.  If this is 
not the case, further optimisation of the antibody concentrations may be worthwhile.  This experiment 
confirms the need for better reagents to stain for CCRL2 tissue sections. 
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Figure 3.10.  Expression of chemokine receptor CCR7 in B cells sorted after a T-cell independent 
response.  CCR7 binds the chemokine CCL19, which has been shown to bind the human CCRL2 receptor 
CRAM (25). *p=0.02 
Key:  
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Figure 3.11.  Expression of chemokine receptors a) CCR1 b) CCR4 and c) CCR5 in B cells sorted after a T-
cell independent response.  These chemokine receptors all bind the chemokine CCL5, which has 
previously been suggested as a ligand for CCRL2 (23). Key: 
 
 
 
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12.  Staining of day 7 spleen from a T-cell independent immune response where CCRL2 shown by RT-
PCR to be present in sorted B cells; a) negative control with DAPI, b) CCRL2 staining with DAPI. 
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3.2.3 Expression of CCRL2 in microdissected spleen sections of a T-cell dependent response 
Mice primed with CGG had the spleen extracted 8 days post NP-CGG immunisation.  Spleen sections 
were cut onto a PALM membrane slide and subsequently dissected using laser assisted microdissection.  
Due to time constraints, only GC (n=4), TZ (n=4) and membrane negative control (n=2) areas were cut.  
Firstly, the sections were tested for the transcription factor IRF-4 and β2M, as a positive control for 
cDNA preparation (figure 3.13a) and were then tested for CCRL2 both short and long form (figure 3.13b).   
The membrane negative control had undetectable levels of IRF-4 and β2M cDNA (data not shown) but 
both GC and TZ areas had detectable levels of both (figure 3.13a), indicating cDNA preparation had been 
successful.  Upon detection of CCRL2 short form, it was shown that it is present in significantly higher 
levels within the GC than within the TZ (p=0.01).  The long form was undetectable in both GC and TZ 
samples (data not shown). 
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Figure 3.13 RT-PCR of microdissected GC and TZ areas of a spleen section 8 days after a TD 
response; a) IRF-4 indicates microdissection and cDNA preparation successful; b) CCRL2 short 
primers. *p=0.01 
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3.3 Cloning of the CCRL2 gene to produce a transfected cell line that can be used for monoclonal 
antibody production 
Previously prepared CCRL2 cDNA was amplified using forward primers that contained an additional 
HindIII or HindIII-ATG restriction site, and a reverse primer containing a SalI restriction site.  The PCR 
product was separated on a 1% agarose gel to ensure amplification was successful and also that the 
CCRL2 amplicon was not contaminated (figure 3.14a, expected product size 1150bp).  Gel containing 
amplified DNA was cut out and the DNA extracted (figure 3.14b).  DNA was purified to a final 
concentration of 8.2ng/µl and 8.8ng/µl for the HindIII and HindIII-ATG DNAs, respectively.   
DNA inserts, plus the plasmid vector pLNCX2 were then incubated with HindIII and SalI restriction 
enzymes within a 2x Tango buffer, as recommended by Fermentas.  Comparison of digested and 
undigested plasmid by 1% agarose gel (figure 3.15a) revealed that the digest had been successful for at 
least one of the enzymes, but whether both enzymes had successfully “cut” the DNA could not be 
confirmed until bacterial transformation.  Therefore, a separate experiment where the plasmid and 
insert were incubated with HindIII and SalI restriction enzymes separately was also conducted. 
Ligation of the CCRL2 insert into the plasmid vector enabled subsequent transformation of bacteria.  
Colonies were produced on both HindIII and HindIII-ATG plasmid ligated plates when the restriction 
enzymes were used both separately or together.  To determine if any bacterial colonies had successfully 
taken up a plasmid containing the insert, a further restriction digest with XhoI and SalI enzymes was 
conducted.  Figure 3.15b shows that transformation had indeed been successful for 3 colonies of HindIII 
primer origin when the enzymes were used in conjunction with one another, however, of the 5 tested 
there were no positive colonies for HindIII-ATG.  Analysing only HindIII-ATG colonies shows that when 
the restriction enzymes were used separately, there was also successful ligation of plasmid and insert 
(figure 3.15c). 
The plasmid inserts were purified from the bacteria and subsequently sequenced (appendix C). Using 
NCBIs BLAST2 analysis software it was determined that both one HindIII and one HindIII-ATG amplified 
DNA construct had an insert with an identical sequence as the original CCRL2 DNA (Appendix A).  
Subsequent Maxiprep of these plasmids was not conducted within this study due to time constraints. 
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Figure 3.14.  1% agarose gels to monitor amplification of CCRL2 from cDNA to be cloned into a plasmid 
vector; a) amplified CCRL2 to be extracted from gel for further cloning studies, expected product size 
1150bp; b) gel after CCRL2 DNA bands cut out 
Key: “M” Marker; “H+” HindIII primer and CCRL2 template; “H-“ HindIII primer no template control; “HA+” 
HindIII-ATG primer and CCRL2 template; “HA-“ HindIII-ATG primer no CCRL2 template control. 
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Figure 3.15.  1% agarose gels after restriction digests; a) comparison of vectors either uncut  or cut with 
HindIII and SalI enzymes; b) vectors purified from bacteria and cut with SalI and XhoI show three colonies 
which have the insert extracted (arrows); c) All plasmids contain HindIII-ATG insert when cut with HindIII and 
SalI separately. 
Key: “M” Marker; “H+” HindIII primer and CCRL2 cDNA; “HA+” HindIII-ATG primer and CCRL2 cDNA; “U/C” 
Uncut plasmid DNA. 
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4. DISCUSSION 
CCRL2 is a member of the atypical chemokine receptor (ACR) family, which also includes DARC and 
D6.  As a family, these receptors tend to cause a chemoattractant gradient of their ligands (31), 
however a ligand for CCRL2 has yet to be described in full.  This study aimed to characterise the 
expression of CCRL2 in various lymphoid organs, particularly identify its expression within the 
germinal centre, and to start the process of monoclonal antibody production for the mouse form of 
the protein. 
4.1 Presence of an alternative splice variant of CCRL2 in the thymus 
Previous studies from members of the group had suggested the presence of an alternative splice 
variant of CCRL2 that are different between the thymus and spleen of mice.  In order to confirm this 
and study other lymphoid tissues, the spleen, inguinal, brachial, mesenteric lymph nodes and 
thymus of wild type mice were compared using differing real-time PCR methods. 
The first experimental approach was to use SYBR-Green RT-PCR, which can identify PCR products 
that differ in size by use of Tmelt curves.  Increasing the temperature causes the double stranded 
DNA to turn into single strands, releasing the bound SYBR Green resulting in a quench in the SYBR-
Green fluorescence.  A difference in the temperature at which the fluorescence of samples is 
quenched could be due to various factors, including mis-priming or primer dimers, but more 
commonly it will be due to differing lengths of the transcripts (a longer transcript requires more 
energy to turn from double stranded into single stranded DNA).  It was suspected that the 
chemokine receptor was longer within the thymus.  NCBI ORF Finder has shown that there are 2 
possible alternative start codons within intron 3 upstream of the published start codon of CCRL2 
consensus sequence.  Therefore, forward and reverse primers were designed to bind exons 2 and 3, 
respectively (appendix A).  The Tmelt data showed a difference between thymus and the spleen and 
inguinal lymph node (ILN) sections.  The thymus section, although with a minor fluorescence change 
at the same temperature as the spleen and ILN sections, gave its highest change in fluorescence at 
3°C higher.  The alternative products from LN and spleen versus thymus in the SYBR-Green PCR has 
also been confirmed by cloning and sequencing by other members within the lab.   
Second, Taqman RT-PCR was conducted, because SYBR-Green PCR has a limited sensitivity.  RT-PCR 
uses a combination of sequence specific primer pairs as well as a sequence specific probe which 
binds between primers.  Increased sensitivity allows for detection of samples with less of the RNA 
present, which were particularly important for microdissected samples.  Primers and probes were 
designed to distinguish unequivocally between the original “short” splice variant of CCRL2 and the 
alternative “long” splice variant.  These primers were successfully optimised for primer and probe 
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concentration.  It was also found that the short primers could be used in multiplex with the 
housekeeping gene β2-Microglobulin.  Within this study, the long primers were not used in 
conjunction with β2-M, as at higher dilutions no signal was present, however it  is possible that this 
was due to lack of template within these samples at the higher template dilutions.  Therefore it 
would be wise to repeat the multiplex reaction for the long primers to confirm or deny whether a 
multiplex reaction is possible. 
Upon using the optimised primers to detect the differing splice variants in tissue sections of wild 
type mice, all sections had similar relative expression of the short form.  The long form was detected 
in thymus as expected from the SYBR-Green PCR data, however it was also observed to a lesser 
extent within the spleen and ILN tissues.  This was also shown when the primers were used in 
singleplex with β-actin.  Due to the nature of the long form primer, it is able to bind any DNA 
contaminating the sample, unlike the short form primer (appendix A).  The relatively high expression 
of this long form within thymus tissue would suggest it is unlikely that the signal is due to DNA 
contamination.  However, whether the smaller signal from the spleen and ILN are genuine signals or 
signals from genomic DNA contamination was not determined.  It would therefore be wise to 
conduct further DNase treatment, as well as repeating the experiment. 
The two experiments described here only describe mRNA expression, which is not an indicator of 
protein levels within the tissue.  Therefore to investigate the expression of CCRL2 protein within 
thymus, spleen and lymph node tissue a Western blot analysis was conducted.  A commercial 
polyclonal rabbit anti-mouse CCRL2 antibody was tested on whole protein lysates of thymus, spleen 
and LN sections of a wild type mouse.  There appears to be two bands of CCRL2 within the MLN, 
which may suggest this true for spleen and thymus sections also (although for the latter two samples 
this could be due to over-exposure).  However, the proteins detected were not at the expected 
product size.  This is particularly surprising, as the antibody was tested for efficacy via Western blot 
of spleen tissue.  It would therefore be irrational to take any conclusions from this test, and a repeat 
of the assay is needed.  
From this data, it can be concluded that CCRL2 is present within the thymus, not only in its original 
short splice variant, but also in a longer form, with part of the third intron.  The human homologue 
to mouse CCRL2, CRAM, is already known to have two splice variants.  CRAM-A, a protein 356 amino 
acids in length, is 12 amino acids longer than CRAM-B.  CRAM-A differs in the 3’ untranslated region, 
3’ coding region and also has a distinct N terminus (32). Generally, it is common for there to be 
transcriptional variability in the chemokine superfamily, as reviewed by Colobran and colleagues 
(33).    
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4.2  The role of CCRL2 within the Germinal Centre 
Staining of CCRL2 by the group within B follicle of the human LN suggested a functional role for 
CCRL2 during the lifetime of the GC (figure 1.5).  Also, Otero and colleagues found antigen-loaded 
dendritic cells were not efficiently trafficked to lymph nodes in CCRL2 knock-out mice (19).  The aim 
of this study was to characterise the expression of CCRL2 at different time-points of a GC-forming 
immune response by using various splenic cell sorted or tissue samples.  A summary of all the 
receptor findings is shown in figure 4.1. 
B cells sorted from a T-independent response were tested for various chemokine receptors using 
Taqman RT-PCR, including CCRL2 short and long forms.  eYFP+ splenic B cells from a QM mouse were 
transferred to WT hosts and the hosts then injected with NP-Ficoll.  Germinal centres in a TI 
response are fully formed by days 3 and 4 and by day 5 it is classed as a mature, and may even start 
to involute at this early stage (30). 
In 2004 Allen et al. found that cells entered the GC light zone, and the orientation of this LZ, was via 
the chemokine receptor CXCR5 (28).  This chemokine receptor was found to be significantly lower on 
GC B cells in comparison to non-activated  follicular B cells , that surround the GC 3 and 4 days post 
immunisation, which agrees with that found by Y. Zhang in 2010 (34).  At day 7 CXCR5 increases in 
expression on GC B cells, and it is not detected on plasma cells.  CXCR5 is responsible for cells 
entering the B follicle and particularly in the GC LZ (28) but downregulates on antibody secreting 
cells (35).   
It was found that the long form of CCRL2 was undetectable in any sorted B cell samples.  The 
possible reason is spleen sections having very small amounts of the CCRL2 transcript (section 4.1).  
However, the original short form was expressed in the B cells in a very specific manner.  On days 3 it 
was in very low levels in activated GC B cells, as was true for day 4.  In contrast, plasma cells 
contained significantly higher levels of the mRNA on day 4.  This difference in expression was lost on 
day 7, where both plasma cells and GC B cells express CCRL2 mRNA in high levels.  Therefore CCRL2 
appears to have a role in early plasma cells and once the GC is mature, its function also spreads to 
GC B cells.   
As CCRL2 mRNA had shown to be present on all B cells at day 7, a section of this spleen was taken 
and fluorescently stained with the CCRL2.  The staining was not specifically localised to B cells and 
was present relatively evenly across the section.  The Western blot analysis (section 4.1) indicated 
cross reactivity of the antibody with unknown proteins, which may be reflected in the 
immunofluorescence staining. 
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Due to its high expression on plasma B cells on both days 4 and 7 it is possible that it is involved in 
plasma cells exit from the GC to enable the production of antibodies in the periphery.  Conversely it 
is not present on GC B cells until day 7.  At this point of a TI response, the GC is starting to 
breakdown and involute.   It is therefore possible that it has a role in GC breakdown, perhaps by also 
allowing GC B cells to exit the GC like the plasma cell counterparts.   
Various ligands for CCRL2 have been described, however independent confirmation of those shown 
in mouse has yet to occur, and a single ligand (CCL19) has been shown in human CRAM (figure 1.4).  
Although these ligands cannot be tested on sorted cells, other receptors known to bind them were 
also tested using RT-PCR.  CCR7, which binds the potential CCRL2 ligand CCL19, had the highest 
mRNA expression of any chemokine receptor tested, with expression similar to that of β2M on all 
active GC-B cell samples every day.  This high expression is not surprising, as CCR7 has previously 
been shown to be upregulated on active B cells (36).   
Contrary to this, on day 7 CCR7 expression is significantly lower on plasma B cells.  CCR7 is known to 
have a vast role in immunity (reviewed by Forster and colleagues (37) ).  In 2005 a study by Okada et 
al. showed that, within LNs, a CCR7-ligand gradient causes movement of B cells towards the T-zone 
boundary to meet T helper cells (38).  Another study has shown that the expression of CCR7 retains T 
cells in the T cell area, emphasising its role within T-zone boundaries (39).  The downregulation of 
CCR7 on plasma cells seen in this study is the same as that found in the review by Cyster (2003) (35) 
because CXCR4 and CXCR3, not CCR7, have roles for the migration of antibody secreting cells. 
Finally, chemokine receptors CCR1, CCR4 and CCR5, which all bind the potential CCRL2 ligand CCL5 
(figure 1.4), were analysed.  All receptors had a surprisingly similar mRNA expression, with a 
significant increase in expression on GC B cells by day 3 and through to day 4, and then a complete 
drop in expression on day 7.  However this final drop was not conclusive due to single samples with a 
very high expression of receptor mRNA compared to the others.  To determine the significance of 
the drop in expression on day 7, there must be a repeat of this experiment.  However, the results as 
described here appear contradict those within previously published data.  Using flow cytometry to 
isolate B cells from human tonsil, Corcione and colleagues deduced that CCR1 was absent and CCR4 
poorly expressed on germinal centre B cells (40).  It is likely this contradiction is due to the results 
from this study being gained during a specific GC timeline for a specific TI antigen, whereas the 
Corcione study isolates B cells from human tonsil without a specific immunisation regimen, resulting 
in GC B cells persistence.   
Interestingly, there is an apparent opposite expression of CCRL2 mRNA in comparison to the 
receptors of CCL5.  CCRL2, whose expression is low and increases at day 7, has opposite expression 
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to that of the other 3 receptors, whose expression are high and then mainly undetectable at day 7.   
This could imply a role for CCL5 within the GCs at days 3 and 4, but less function at day 7, when the 
GCs involute.   
CCRL2 is a member of the atypical chemokine receptor family, which are also known as interceptors 
(internalising receptors) due to their ability to take up the chemokine ligand into the cell (41).  From 
the data here, it is possible to suggest that CCRL2 is not present on GC B cells in the early stages of 
the GC reaction because they require the ligand CCL5 (and so receptors CCR1, CCR4 and CCR5) to 
elicit a function, perhaps retention within the GC.  By day 7, when GC involution in nearing, the B 
cells reduce expression of the receptors to CCL5 and increase the expression of CCRL2 to ensure any 
binding of CCL5 does not elicit the response, but enable internalisation of the ligand, therefore 
allowing for GC breakdown.   
Finally, because the previous RT-PCR data had shown an increase in CCRL2 mRNA expression at day 
7, a spleen sample at day 8 after a TD antigen immunisation was taken.  A combination of 
histological staining, microdissection and RT-PCR would be used to characterise specific areas of the 
spleen CCRL2 mRNA is expressed.  Unfortunately, due to time constraints, only 9 sections were 
microdissected.  The results show that CCRL2 short form mRNA is expressed within the GC, and 
expression was also detectable in the TZ, with significantly lower levels.   
It is difficult to imply any conclusion from the TZ results without knowledge of how CCRL2 is 
expressed in the TZ over time.  However, because of its TZ expression, it is possible that CCRL2 is not 
just expressed on B cells, even though these are the cells mainly tested within this study. 
The high expression of CCRL2 within the GC at day 8 within the TD response could support the 
previous data of high expression of CCRL2 mRNA in day 7 GC B cells.  It would be interesting to see if 
this expression is decreased in days 3 and 4 of the response, as implied by cell sorted results.  
Further, dissection of plasma cell areas would enable confirmation of plasma cells also having high 
expression of the chemokine receptor at this, and earlier, stages. 
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Figure 4.1.  Expression of chemokine receptors during a Germinal Centre response.  Expression on B cells or 
within the Germinal Centre and T-zone.  Receptors CCRL2, CXCR5, CCR1, CCR4, CCR5 and CCR7 all tested unless 
otherwise stated; a) Day 1 post-immunisation only tested for CCRL2 which is not present on any eYFP+ cells; b) 
Day 3 post-immunisation, germinal centre B cells; c) Day 4 post-immunisation, only CCRL2 tested for plasma 
cell mRNA expression, all tested for GC B cell expression; d) Day 7 post immunisation and difference of receptor 
mRNA between germinal centre or plasma cells; e) Day 8 post immunisation and only CCRL2 tested on 
microdissected germinal centre or T-zone areas; f) legend.  Pictures adapted from The Thesis of Y. Zhang (34) 
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4.3 Cloning of the CCRL2 gene to produce a transfected cell line that can be used for monoclonal 
antibody production. 
As well as assessing CCRL2 directly, the final part to this study was to start the process of monoclonal 
antibody production against mouse CCRL2.  Although a human version of the antibody is available, 
currently there is only a polyclonal antibody available for mouse CCRL2 (Sigma-Aldrich) which has 
been used within this study for both Western blot and histology analyses.  Within this study, both of 
these analyses gave inconclusive data.   The Western blot results, however, are probably due to 
personal technique rather than the antibody itself.  It is therefore paramount to acquire a specific 
monoclonal antibody for use within these in vitro studies to ensure a signal is not from unspecific 
protein binding. 
Within this study the first stages of monoclonal antibody production has been successful.  CCRL2 
DNA, still as its original sequence, has been effectively cloned into a plasmid vector.  There are two 
bacterial strains expressing this vector available, the first contains the CCRL2 DNA only, and the 
second contains CCRL2 DNA with an additional ATG start codon.  Further study will suggest which of 
these CCRL2 variants, once transfected into a mammalian cell line, enables the most efficient 
expression of CCRL2. 
4.4 Future Work 
Further characterisation of the longer form of CCRL2 is required.  Within this study it was shown that 
the longer form of CCRL2 is expressed within the thymus, which confirms a previous study within the 
group.  Various questions have yet to be answered – where is the alternate splice site and so what is 
its size?  Does the longer form have different ligands or function to the shorter form?  And finally, 
what is the tissue expression of the long form, are the signals in the spleen and ILN genuine? 
Further mRNA expression data is needed.  It would be useful to know the expression of the various 
chemokine ligands on plasma cells (for example plasma cell expression is only seen on days 4 and 7, 
and only CCRL2 has been tested on day 4 plasma cells).  Further, microdissection of different 
timepoints in the immune response would allow further investigation into CCRL2 expression in 
specific areas of the spleen instead of only cell subsets.  Also, microdissection would allow detection 
of possible related chemokines. 
To utilise the currently available polyclonal CCRL2 antibody to its fullest potential, it should be 
titrated to deduce optimal concentration for staining and Western blot techniques.  This will ensure 
any data gained from these experiments are genuine results and not background. 
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Finally, continuation of the methods to produce a monoclonal antibody against mouse CCRL2 must 
be conducted.  This antibody could allow further analysis of tissues for CCRL2, including histological 
techniques, FACs analysis and ELISA techniques. 
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ABSTRACT 
 
Many proteins function in recruitment of lymphocytes from circulation and subsequent 
transmigration into tissues.  Definition of these proteins has been through in vitro models which 
mimic the in vivo processes.  In order to study lymphocyte recruitment, this study utilised a flow 
assay, in which the circulation is simulated by perfusion of lymphocytes over an endothelial 
monolayer.  The aim was to characterise how the cytokines TNF-α and IFN-γ affect endothelial 
recruitment and behaviour of peripheral blood lymphocytes (PBL), and also define chemokine 
receptors involved in this process.  It was observed that TNF-α treated endothelium recruits less PBL, 
and this reduction is due to an inefficient capture of CD4+ T cells.  In contrast, NK cells were 
efficiently recruited to cytokine stimulated endothelium.  After 1 hour of wash, the endothelium did 
not lose any bound PBL, suggesting PBL do not readily exit back to circulation once bound.  As 
different cytokine stimulated endothelium produces different chemokines, the chemokine receptors 
CXCR3 and CCR5 were functionally blocked on PBL.  Contrary to previous reports, blocking of CXCR3 
had no effect on lymphocyte recruitment, which may be explained by the antibody used here 
blocking different receptor-ligand interactions, or blocking different isoforms of the chemokine 
receptor. 
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ABBREVIATIONS 
 
CHO Chinese Hamster Ovary cell line 
EDTA Ethylenediaminetetraacetic Acid 
GAG Glycosaminoglycan 
GPCR G protein coupled receptors 
HMEC Human Microvascular Endothelial Cells 
HUVEC Human Umbilical Vein Endothelial Cells 
ICAM-1 Intercellular Adhesion Moleculae-1 
IFN-γ Interferon-γ 
LFA-1 Lymphocyte Function-Associated Antigen-1 
MADCAM-1 Mucosal Vascular Addressin Cell-Adhesion Molecule-1 
PBL Peripheral Blood Lymphocytes 
PBSA Phosphate Buffered Saline with Bovine Serum Albumin at 1.5% 
PBSA2% Phosphate Buffered Saline with Bovine Serum Albumin at 2% 
RANTES Regulated upon Activation, Normal T cell Expressed, and Secreted; Chemokine CCL5 
RT Room Temperature 
TNF-α Tumour Necrosis Factor-α 
TNF+IFN Endothelium treated with both TNF-α and IFN-γ 
VCAM-1 Vascular Cell Adhesion Molecule-1 
VLA-4 Very Late Antigen-4 
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5. INTRODUCTION 
 
In order to protect the host, leukocytes must exit the blood and enter into tissues.  To define the 
molecules involved in this process, different in vitro models have been utilised to mimic leukocyte 
capture and transmigration.  Static assays, which involve the incubation of leukocytes with 
endothelium, allow for lymphocyte adhesion and transmigration.  Flow assays, however, force 
leukocytes over endothelium under various shear rates causing the capture and rolling of the 
leukocyte along the endothelial surface, before stable adhesion and transmigration.  The following 
summarises how these models have shown mechanisms by which lymphocytes adhere to, and 
transmigrate into, endothelial tissue. 
5.1 A brief overview of leukocyte migration 
There are four very general steps which are involved in leukocyte capture and subsequent 
transmigration into tissue; 1) tethering and rolling along to the endothelial surface; 2) activation of 
integrins; 3) firm adhesion and migration over endothelium 4) transmigration into tissue (figure 5.1) 
(42).  The latter step is split into many stages, including transit across the endothelial monlayer, 
through the underlying basement membrane and into the stroma (43).  There are different signals 
which govern this process between different leukocytes, with the focus of this study being 
lymphocytes.   
5.2 Lymphocyte capture to endothelium – the role of cytokines and adhesion molecules 
Cytokine release by endothelium and cells of the innate immune system signals to lymphocytes the 
need to exit circulation.  Different cytokines are released by different cells during differing infections, 
with often a proinflammatory phenotype.  For example, large amounts of tumour necrosis factor-α 
(TNF-α) is produced in response to lipopolysaccharide and other bacterial products (44). This 
cytokine is mainly produced by macrophage, but also by other cell types including endothelium (44). 
On the other hand, interferon-γ (IFN-γ) and its receptor are widely expressed with potent antiviral 
effects (45). 
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Figure 5.1  Leukocyte adhesion cascade.  The close proximity of the leukocyte to the endothelial 
membrane enables capture and rolling along the endothelial surface, with firm adhesion requiring 
activation of the leukocyte first.  Once the leukocyte is stably adhered, it may start spreading and 
crawling, which can eventually lead to transmigration through the endothelial layer and into the 
tissue below.  Adapted from Ley et al. (2007)(42) 
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Stimulating endothelium with both TNF-α and INF-γ within flow models of the circulatory system 
increases attraction of lymphocytes to endothelium in comparison to the control (46).  TNF-α 
treatment on endothelial cells causes the induction of surface expression of P-selectin, as shown by 
indirect immunofluorescence with anti P-selectin antibody (47).  P-selectin is a member of the 
selectin family of molecules, named as to whether they were discovered on leukocytes (L-selectin), 
platelets (P-selectin) or endothelium (E-selectin) (48-49).  Luscinskas and colleagues, by blocking the 
selectins with antibodies and detecting adherence to human umbilical vein endothelial cell (HUVEC) 
monolayers under flow, established that P-selectin mediates the contact between lymphocytes and 
the endothelium (47).  This was confirmed in another study, where blocking the function of P-
selectin on TNF-α treated HUVEC inhibited rolling of T cells on endothelium (50).  The latter study, 
amongst others, also established a requirement of E-selectin in the capture and rolling of 
lymphocytes, by utilising either L-cell or Chinese hamster ovary (CHO) cell transfectants of E-selectin 
(50-51).  The data from these studies highlights the importance of selectins in the initial capture and 
rolling of lymphocytes. 
The role of cytokines in activating endothelium for lymphocyte capture is emphasised in a study by 
Oppenheimer-Marks et al., who utilised control endothelium and that stimulated with IL-1 to deduce 
the molecules involved in lymphocyte adhesion (52).  This study determined the parts played by of 
vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) in T-cell 
adhesion, via way of a static assay (52).  Blocking of VCAM-1 function inhibits T-cell adhesion on IL-1 
stimulated endothelium, but blocking ICAM-1 had no effects (52).  However, the opposite is true in 
unstimulated endothelium (52).  Comparison of flow and static assays using L-cells which are 
transfected with VCAM-1 or ICAM-1 also emphasise their different roles within adhesion (51).  Under 
static conditions, T cells adhered to both transfected cell lines – a property which was blocked using 
antibodies against the molecules (51).  However, VCAM-1, but not ICAM-1 transfectants were able to 
support adhesion under flow, thus suggesting VCAM-1 has a role in all stages of lymphocyte 
adhesion, whereas ICAM-1 is only involved in stabilising the attachment (51).  Confirmation that 
ICAM-1 is not involved in stable adhesion of lymphocyte attachment under flow was shown when 
treatment of HUVEC with blocking antibody to the molecule did not have an effect (50).   
5.3 Stable lymphocyte adhesion to endothelium – the role of chemokines and integrins 
VCAM-1 interacts with β1-integrins expressed on the lymphocyte, and blocking these caused the 
lymphocyte to roll quicker along TNF-α activated HUVEC, which is not the case for β2-integrins (47).  
This emphasised that the different integrin subsets have different roles in lymphocyte adhesion to 
endothelium.  In order to express integrins and allow for stable adhesion, the lymphocyte must be  
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activated.  Activation is caused, in part, by chemotactic cytokines (“chemokines”).  Chemokines are 
defined via a set of 4 conserved cysteine residues linked by disulphide bonds (10).  The two major 
subfamilies of chemokines are named CC or CXC, depending on whether the two first cysteines are 
adjacent or separated by another amino acid (10).  Chemokines bind to G protein coupled receptors 
(GPCRs) on the cell surface to produce their effect on the target cell.    GPCRs are “serpentine” 
receptors, with 7 transmembrane helices connected by loops. 
The lymphocyte is in close contact with the endothelial glycocalyx due to initial tethering and rolling 
(53).  Within this polysaccharide matrix are bound chemokines, secreted by the activated endothelial 
cells.  The chemokines bind to, and are immobilised by, glycosaminoglycans (GAGs) via the motif 
BBXB (where B is a basic amino acid), as shown by mutagenesis studies of CCL5 (54).  Using 
chemokine mutations, Proudfoot et al. demonstrated that GAG binding is required for the in vivo 
activity of certain chemokines (55) (reviewed by A. Rot (2010) (56)).  Upon binding to the serpentine 
receptor, dissociation of the G-protein α- and βγ- subunits causes a signalling cascade which 
cumulates in the release of talin (57).  Activation of the integrin is subsequently caused by the 
binding of talin to the β tails of integrin (43, 57-58).   
There have been numerous studies deciphering the role of various chemokines in lymphocyte 
recruitment to endothelium.  The present study will observe the effect of blocking two chemokine 
receptors, CCR5 and CXCR3, on lymphocyte recruitment.  Below summarises the current literature 
relating to these two particular chemokine receptors. 
5.3.1 CCR5  
The chemokine CCL5, (sometimes referred to as RANTES; Regulated upon Activation, Normal T cell 
Expressed, and Secreted) is a ligand for CCR5.  However, Baltus and colleagues observed that CCR5 
does not mediate memory T cell arrest to human microvascular endothelial cells (HMEC) treated 
with CCL5 under a shear flow rate of 0.15Pa (59).  This was interesting as another receptor of CCL5, 
CCR1, was capable of CCL5 mediate memory T cell arrest under the same conditions (59).  
Nonetheless, CCR5 has been demonstrated to be required in TH1 cell arrest, as using monoclonal 
antibodies against CCR5 Lim et al. showed a significant decrease in accumulation of TH1 cells on TNF-
α treated endothelium (60).   
5.3.2 CXCR3 
In 1998 Piali and colleagues examined the adhesion of IL-2 stimulated memory T cells on HUVEC 
treated with TNF-α or IFN-γ under a shear flow rate of 0.1Pa (61).  In this study the lymphocytes 
rapidly adhered, but the effect was reduced with addition anti-CXCR3 antibody (61).  This is                 
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unsurprising, since the lymphocytes used all expressed CXCR3 strongly (61).  These results have not 
only been observed in HUVEC -  Curbishley et al described CXCR3 activation promotes adhesion and 
transmigration of in vivo activated liver T cells (T cells isolated from diseased livers) across human 
liver endothelium under a shear flow rate of 0.05Pa (53).  These results were both confirmed later, 
when McGettrick et al. showed anti-CXCR3 treatment caused a 75% reduction in lymphocyte 
adhesion to TNF-α with IFN-γ (TNF+IFN) treated endothelium at a shear flow rate of 0.1Pa (62). This 
inflammatory-dependent CXCR3 stabilisation is likely due to CXCR3 ligands requiring the 
inflammatory cytokine IFN-γ for their expression.   
5.4 Factors in lymphocyte transmigration through endothelium 
Chemokine signalling is not only important for integrin activation, but their signalling cascades also 
incur other changes to the lymphocyte.  Binding of the chemokine causes dephosphorylation of 
cytoskeletal ERM proteins (ezrin/radixin/moesin), enabling microvillus resorption and polarisation 
(63-64).  In addition to microvilli resorption, the chemokines have a role in actin skeleton 
organisation and thus transmigration.  This was emphasised in a study by Ding and colleagues, who 
noted that lymphocyte transmigration in both TNF-α and IFN-γ activated HUVEC was inhibited by 
addition of pertussis toxin (65).  Further evidence was found when the binding of a specific 
chemokine, CXCL9, rapidly activated small GTPases RhoA and Rac1 (66), and Rho GTPases have long 
been implicated as regulators of the actin cytoskeleton (67). 
Transmigration of activated T cells (T cells preincubated with IL-2) is upregulated when the lower 
chamber of a static assay is incubated with the chemokine CCL5 (68).  In addition to CCL5; CCL2 and 
CCL3 have been shown to induce transmigration of resting memory T cells specifically, whereas 
CXCL12 is capable of inducing transmigration in both naive and memory T cell subsets (65).   
The role of chemokines in lymphocyte transmigration has been shown to be affected by the cytokine 
treatment of HUVEC.  CXCL11 increases transmigration across TNF-α, but not IFN-γ, nor TNF+IFN 
stimulated HUVEC (69).   This is due to TNF-α stimulated HUVEC being the only condition which does 
not produce CXCL11 (69).   
Transmigration is not only dependent on chemokines and the subsequent signalling cascades which 
they produce.  For example, by incubating peripheral blood lymphocytes (PBL) with an antagonist 
against the  prostaglandin D2 receptor, DP2, Ahmed et al. observed inhibition of transmigration, 
showing that prostanoid signals are also required for lymphocyte transmigration (70).  
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As with adhesion, transmigrating lymphocytes utilise different molecules depending on the 
activation state of the endothelium and the lymphocytes themselves.  Activated T cells have a 3 to 4 
fold increase in transmigration through HUVEC than resting T cells (71).  These T cells utilise the 
expression of the ICAM-1 counter-receptor lymphocyte function-associated antigen-1 (LFA-1), yet 
resting T cells do not (71).  Conversely, another study stated that ICAM-1 is required for 
transmigration of T cells, independent of stimulation of either HUVEC or the T cells themselves (52).  
Interestingly, blocking the function of both LFA-1 and very late antigen-4 (VLA-4; the intergrin 
counter-receptor of VCAM-1) abolishes T cell transmigration (69). 
Once a cell has transmigrated through the endothelium, it is still able to reverse-transmigrate back 
out again.  Recent in vitro data has shown some lymphocytes undergo transitions in and out of 
endothelial monolayers in both static and flow conditions (46).  This “frustrated” phenotype, implies 
a separate signal is required for lymphocyte migration into stroma once transmigration has occurred 
(46).  Whether this phenomenon is from a specific subset of lymphocytes remains to be seen, 
however, it is currently unknown that if without the suggested signal required “frustrated” 
lymphocytes will exit the endothelium and return to circulation. 
5.5 Specific lymphocyte subtypes preferentially transmigrate through endothelium 
The ability to collect, purify and subsequently stain for specific lymphocyte markers has enabled 
determination of which lymphocyte subtypes have transmigrated through the endothelial 
membranes.  CD8+ T cells have a greater capacity to transmigrate than CD4+ T cells, and within the 
latter, memory CD4+ T cells transmigrate more efficiently than naive (72).  Further to this, TNF-α and 
IFN-γ treatment of HUVEC increases the transmigration capacity of memory CD4+ T cells, whereas 
activation of the T cells increases the ability for transmigration of naive CD4+ T cells (65, 73).   
Chemokines have also been implicated in transmigrational ability; the chemokine CXCL11 increases 
transmigration of both memory CD4+ and CD8+ T cells (69).  Opposite to this, the molecule CD31 is 
negatively correlated with transmigration, probably due to its expression being closely linked with 
that of the naive T cell marker, CD45RA (74).    
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5.6 Aims of project 
 
 Determine the differences in lymphocyte adhesion to cytokine treated endothelium 
 Observe the effect of time on the number of lymphocytes adhered to the endothelial 
surface 
 Characterise which lymphocyte subtypes preferentially bind to cytokine treated 
endothelium 
 Block chemokine receptors on lymphocytes and deduce if there is an effect on recruitment 
to endothelium 
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6. MATERIALS AND METHODS 
 
6.1 Endothelial cell culture 
The primary cell line human umbilical vein endothelial cells (HUVEC) were isolated by Phil Stone in 
accordance with protocol described (75).  HUVEC were grown in complete media (Medium 199 with 
glutamine (Gibco Invitrogen Compounds, Paisley, Scotland) with gentamycin sulphate (35µg/ml), 
human epidermal growth factor (10ng/ml), fetal calf serum (20% w/w heat-inactivated) and 
hydrocortisone (1µg/ml; all from Sigma-Aldrich, Poole, UK) at 37˚C in a 5%CO2 incubator.   
Immortalised cell line human microvascular endothelial cells (HMEC; gift of Francisco Candel, CDC, 
Atlanta, GA) were recovered from liquid nitrogen, resuspended in complete media and cultured as 
HUVEC.    
6.1.1. Preparation of Ibidi slide for flow assay. 
Confluent endothelial cells were rinsed with 2ml 0.02% EDTA and subsequently incubated for 1-2 
minutes with a 2:1 ratio of trypsin:EDTA (both Sigma-Aldrich) to detach cells.  To neutralise the 
trypsin, 8ml of complete media was added and the solution, which was then centrifuged at 1500rpm 
for 5min.  Cells were resuspended in complete medium and 35µl of this added to µ-Slide VI0.4 slides 
(Ibidi, Martinsried, Germany, figure 6.1) to fill the channel.  Slides were incubated at 37˚C 5% CO2 for 
40min to ensure adherence to the channel surface, after which the wells were topped up with 
complete media.  Slides were left within a humidity chamber for 24hr at 37˚C in a 5% CO2 incubator. 
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Figure 6.1 Ibidi  µ-Slide VI0.4 slides in which HMEC or HUVEC were seeded for flow assay.  Cells were 
grown within the channels across the centre of the slide, and wells at the end contained fresh 
complete media to provide nutrients for the cells.  Wells at either end represent the inlet and outlet 
of the channels. 
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6.2 Isolation of human peripheral blood lymphocytes 
Blood from healthy volunteer donors was collected in tubes containing potassium EDTA (Sarstedt, 
Leicester, UK) after informed consent.  Leukocytes were separated in a density gradient, where 
2.5ml of Histopaque 1077 was layered onto 2.5ml of Histopaque 1119 (both Sigma-Aldrich), onto 
which 5ml of the blood was added.  This was centrifuged for 40min at 2500rpm to separate blood 
cells to different layers.  Mononuclear cells were retrieved from the top of the gradient, between 
plasma and Histopaque 1077 (figure 6.2).  Mononuclear cells were washed twice in phosphate 
buffered saline (containing calcium chloride and magnesium chloride) with 0.15% bovine fraction V 
albumin (all Sigma-Aldrich) (“PBSA”) for 5min at 1500rpm.  To deplete the mononuclear cells of 
monocytes, cells were resuspended in 1ml of PBSA and incubated in a 25cm3 cell culture Falcon flask 
for 30min at 37˚C 5% CO2 causing monocytes and activated PBL to adhere to the flask surface.  
Enriched peripheral blood lymphocytes (PBL) were gently washed in PBSA and centrifuged for 5min 
at 1500rpm.  Cells were resuspended in 1ml of PBSA.  Cells were counted using Cellometer Auto T4 
(Nexcelom Bioscience, Lawrence, MA, USA) and diluted to either 1million/ml or 2million/ml using 
PBSA.  If the experiment required, PBL were incubated for 15min with a function blocking antibody 
against CCR5 clone number 45531 (20µg/ml) or against CXCR3 clone number 49801 (10µg/ml, both 
R&D Systems, Minneapolis, MN). 
6.3 Flow assay 
Slides containing HUVEC or HMEC-1 were treated with either tumour necrosis factor-α (TNF-α, R&D 
Systems) (100U/ml), interferon-γ (IFN-γ) (10ng/ml, Peprotech Inc., London, UK) or both 24 hours 
prior to start of flow assay.  
The flow system was set up within a Perspex box at 37°C (figure 6.3), as previously described (76-77).  
The slide was visualised using a 20x Leitz Labovert phase contrast microscope and images recorded 
onto a video cassette tape.  All tubing was primed with wash buffer to rid the system of bubbles 
before any tubing was connected to the slide.  The syringe pump (Harvard Apparatus PHD2000 
Programmable, Instech Laboratories) was set to a flow rate of either 0.4ml/min or 0.8ml/min, 
equivalent to a wall shear stress of 0.05Pa or 0.1Pa respectively (See the Ibidi website, www.ibidi.de, 
for calculation). Wash buffer was pumped through the system for 1 minute, after which the 
electronic valve (Lee Products, Gerards Cross, UK) was switched on for 4min to enable a bolus of 
PBL.  The slide was then washed for 2min, after which recordings of 10 fields of view down the 
centre of the slide were made onto videotape.  For calculation of migration velocities, a single field 
of view was recorded for 10min.  Finally, another 10 field recording was conducted down the centre 
of the slide as before.   
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Figure 6.2 Representation of separation of blood components using a Histopaque gradient.  PBL 
were collected from the mononuclear cell layer, between the plasma and histopaque. 
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Figure 6.3  Schematic representation of the flow assay which mimics the circulatory system within 
post-capillary venules.  Either wash buffer or PBL was pulled through the slide via a pump, 
depending on whether the electronic valve was off or on, respectively. A camera, located on the 
microscope, was able to record the PBL and endothelium located on the slide.  All parts of the 
equipment, minus the pump, were kept within a box heated to 37°C. 
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6.3.1. Analysis 
Videos were digitised and analysed offline using Image Pro Plus software (DataCell Ltd., 
Finchampstead, UK).  Lymphocytes were counted and classed as either adherent-rolling (phase 
bright, spherical cells moving over surface slower than free flowing cells); adherent-stationary 
(phase bright, spherical cells that appear to “vibrate” on endothelium surface) or transmigrated 
(phase dark and distorted in shape) as previously described (46) (figure 6.4).  The velocity of cells 
migrating underneath the endothelium was measured in a single field over 10min.  In each digitised 
image cells were outlined and the centre of the cell determined.  Migration velocity was calculated 
as the average distance the centre of the cell moved per minute.  In order to analyse migration 
directionality, the original (x,y) coordinates  of the cell were taken as the origin (0,0) and all 
subsequent co-ordinates re-calculated relative to this. 
6.4 Flow cytometry 
6.4.1. Flow cytometry analysis of perfused PBL cells 
Supernatants from the slides were collected and remaining cells within the channel removed by 
trypsinisation (section 6.1.1) and combined with the supernatants.  Samples were incubated with 
fluorescently-tagged antibodies (table 6.1) for 30mins at 4°C in the dark.  Samples were washed and 
fixed with 2% paraformaldehyde (Sigma-Aldrich) and stored at 4°C until analysis.  Labelled cells were 
analysed using CyAN FACS analyser (Beckman Coulter, UK) with analyser plus offline analysis 
controlled with Summit v4.3 software. 
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Figure 6.4 Adherent cells on a monolayer of HUVEC. The phase bright round lymphocyte was stably 
bound to the surface (eg. solid arrow).  The phase dark distorted lymphocyte had transmigrated 
through the endothelial layer and was migrating underneath (eg. dotted arrow). 
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Table 6.1. Primary antibodies used for flow cytometric analysis of PBL isolated from flow assay. 
 
 
 
 
 
 
 
 
Epitope Fluorophore Isotype Expression Company 
CD3 APC IgG1 T-cell Invitogen 
CD4 PacBlue IgG2b Subset of T cells eBioscience, UK 
CD8 FITC IgG2a Subset of T cells 
BD Biosciences, 
Oxford, UK 
CD45RO PE IgG1 Memory T cells BD Biosciences 
CD20 PeCy7 IgG1 Mature B cells 
AbCam, 
Cambridge, UK 
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6.4.2.  Flow cytometry analysis of PBL treated with blocking antibodies against CXCR3 or CCR5 
PBL were treated with function-blocking antibodies against CXCR3 and CCR5 as described (section 
6.2).  PBL were washed and treated with secondary antibody, polyclonal goat anti-mouse 
immunoglobulin, FITC conjugated (Dako, Ely, UK) for 30mins at 4°C in the dark.  As a comparison 
fresh PBL were incubated with either FITC conjugated anti-CXCR3 (R&D Systems) of Alexa Fluor 
conjugated anti-CCR5 (BioLegend, San Diego, CA, USA).  Samples were then fixed and analysed as 
described in 6.5.1.   
6.5 Statistical analysis 
Data was plotted into GraphPad Prism version 5 which analysed the effects of multiple treatment via 
two-way ANOVA.  If applicable, individual treatments were compared using a Bonferroni test.  
Statistical significance was accepted for any p value less than 0.05. 
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7. RESULTS 
 
7.1. Effect of different cytokine treatments on lymphocyte recruitment to HUVEC 
7.1.1 Effect of cytokine treatment on adherence 
Initial experiments examined recruitment of peripheral blood lymphocytes to HUVEC.  The 
endothelial cells were treated with either TNF-α, IFN-γ, or a combination of both and subsequently 
was perfused with PBL.  Adherence and behaviour of PBL was then determined.  All cytokine treated 
endothelium were capable of lymphocyte capture from flow, however, less than 1% of the perfused 
lymphocytes bound to the endothelial layer; this was true for all three cytokine treated conditions.  
The TNF+IFN condition consistently bound more PBL than the use of cytokines individually (figure 
7.1), although this was not statistically significant.  It is shown here there are no differences in 
adhesion between 2 and 16 minutes of washing, supporting previous data (46), which indicates 
stable lymphocyte adhesion to the endothelium. 
Lymphocyte behaviour was determined by video recording of 10 random fields of view from the top 
(inlet) to the bottom (outlet) of the channel.  As these experiments were conducted in Ibidi slides, 
different to the chamber slides previously used (46), it was important to ensure even binding of PBL 
throughout the channel.  PBL were randomly distributed along the channel, with no bias towards 
either the inlet or outlet (figure 7.2).  Of the four TNF+IFN experiments, one had considerably lower 
binding in comparison to the other three (figure 7.2c).  This variation could explain the lack of 
significant difference in adherence in figure 7.1. 
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Figure 7.1 The effect of cytokine treatment on adherence of lymphocytes to HUVEC from flow.  
HUVEC were stimulated with either TNF-α, IFN-γ or both, 24hours before a 4minute perfusion of PBL.  
PBL adherence was determined after 2 or 16 minutes of washing.  Data are the mean ± SEM for 4 
independent experiments. 
Key: 2 minutes post PBL perfusion; 16 minutes post PBL perfusion 
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Figure 7.2 Distribution of adhered PBL along the centre of the Ibidi channel.  PBL adhesion to a) 
TNF-α; b) IFN-γ; c) TNF+IFN treated endothelium was assessed after 2mins of washing by recording of 
10 random fields down the centre of the Ibidi channel from inlet (field 1) to outlet (field 9).  The inlet 
is the entry point of the slide for wash buffer or PBL and the outlet the exit point.  Four different 
experiments are shown in black, with the mean highlighted in red. 
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Upon adhering to the endothelial monolayer, lymphocyte behaviour can be defined as rolling, 
stationary or transmigrated through the surface (figure 6.2).  For all cytokine treatments only 5% of 
lymphocytes were defined as rolling at 2min, and this value further decreased at 16min due to stable 
adhesion of the lymphocytes (figure 7.3a-b).  At 2 minutes of washing, the majority of PBL were 
firmly adhered to the endothelial surface (approximately 60-80% depending on cytokine treatment), 
with the remaining transmigrated through the endothelial cell surface (20-40%).  There was a 
significant increase in the percentage of transmigrated cells at 16min compared to 2min across all 
cytokine treatments (figure 7.3b).  However, this is different to previous studies, which suggested 
that transmigration did not increase over time (46).   Significantly less PBL transmigrated when TNF-
α was used to treat the endothelium compared to IFN-γ treatment (figure 7.3c), which is consistent 
with previous reports (46). 
 7.1.2. The effect of cytokine treatment on the behaviour of transmigrated PBL 
Once a lymphocyte has transmigrated underneath the endothelial layer it is able to move around 
beneath the surface.  The direction of this movement was random and not dictated by the flow 
above the endothelial layer (figure 7.4).  Lymphocytes migrated underneath the surface at 
approximately 7.5-8µm/min (consistent with previous data (46)), and this was unaffected by 
cytokine treatment (figure 7.5a).  However, the variation in the velocities of individual cells was quite 
considerable, ranging from 1-21µm/min (figure7.5b). 
It has previously been demonstrated that lymphocytes appear to be “frustrated,” and undergo 
numerous transitions above and below the endothelial monolayer (46) (figure 7.6).   The frustrated 
migration was observed here over a 10 minute period, with cells making between 1 and 6 transitions 
(figure 7.7a) with similar trends observed for all cytokine treatments (figure 7.7b).  To assess 
whether these “frustrated” cells eventually left the endothelium and returned to flow, a single field 
was recorded every 10 minutes for 1 hour and the number of remaining cells determined (table 7.1 
and figure 7.8).  The number of transmigrated cells gradually increased with time, peaking at 30min, 
after which the number remained relatively constant.  Only 2 phase bright cells stayed stationary 
throughout the hour, suggesting some cells are pre-disposed to not transmigrate through the 
endothelial monolayer (figure 7.8).  As the total number of cells did not decrease over the hour, the 
frustrated cells did not re-enter flow within this time frame (table 7.1). 
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Figure 7.3 Effect of cytokine treatment on the behaviour of adherent lymphocytes.  The behaviour 
of adhered PBL was designated as rolling or stationary on the endothelial surface or transmigrated 
through the endothelium.  The effect of cytokine treatment on each PBL behaviour was assessed 
after a) 2 mins; b) 16mins of washing and difference between cytokines were significant (p<0.05).  c) 
effect of time on the behaviour of captured PBL.  Data is mean ± SEM for 4 independent experiments.   
*p<0.05, **p<0.01. 
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Figure 7.4 Direction in which transmigrated PBL moved on cytokine treated endothelium.  All cells 
begin at the origin and lines represent direction of cell movement during 10minutes for endothelium 
treated with a) TNF-α n=20; b) IFN-γ n=13; c) TNF+IFN n=38.  The y axis is equivalent to the direction 
of flow with the top of the y axis signalling top of the field of view, the x axis left to right.   
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Figure 7.5 Effect of cytokine treatment on the migration velocities of transmigrated PBL.  
Migration velocities were determined from a single 10min field recorded after 5min of washing; a) 
Data are mean ± SEM for migration velocity from 3 (IFN-γ) or 5 independent experiments; b) 
velocities of all individual migrating cells from all experiments (Data are mean ± SEM for TNF-α n=21; 
IFN-γ n=16; TNF+IFN n=41) 
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Figure 7.6 Micrographs showing a "frustrated" cell migrating in and out of the endothelium.  A 
single cell, marked with an asterisk, was followed over 5min as it changed between phase dark and 
phase bright throughout the pictures.  The snapshots represent the cells movements over 5 minutes.  
The cell undergoes 4 transitions. 
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Figure 7.7 Effect of cytokine treatment on the transitional ability of individual lymphocytes over 10 
minutes.  A single field was recorded for 10min after 5min of washing and the migratory behaviour 
of individual cells assessed; a) effect of cytokine treatment on migratory transits of individual cells (a 
transit is defined by whether a cell transmigrates (phase bright to phase dark; open points) or 
reverse-transmigrates (phase dark to phase bright; blacked); b) percentage of total cells which 
undergo a transition irrespective of their start position as mean ± SEM.  Data are from 4 (IFN-γ) or 5 
independent experiments. 
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Table 7.1 Ongoing behaviour of PBL adhered to TNF+IFN treated endothelium over 1hr.  A single 
field was recorded every 10min for 1hr and the PBL behaviour at each time point taken.  This data is 
from a single experiment. 
 
Time 
(minutes) 
post PBL 
perfusion 
Rolling Lymphocytes 
Stationary 
Lymphocytes 
Transmigrated 
Lymphocytes 
Total number 
of 
Lymphocytes Number % Number % Number % 
10 1 3.03 14 42.42 18 54.54 33 
20 1 3.13 10 31.25 21 65.63 32 
30 2 5.13 8 20.51 29 74.36 39 
40 2 5.26 9 23.68 27 71.05 38 
50 0 0 9 25.00 27 75.00 36 
60 0 0 10 27.03 27 72.97 37 
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Figure 7.8 Micrographs of lymphocyte behaviour on TNF+IFN treated endothelium over 1hr.  
Images were taken every 10min of a single field.  Highlighted in red and blue are 2 phase bright 
stationary cells, which remain stationary for the duration of the recording. 
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7.1.3. The effect of cytokine treatment on recruitment of PBL subtypes. 
In order to determine which lymphocyte subpopulations were recruited to the endothelial cell 
surface, the adherent cells were trypsinised and collected, stained for various lymphocyte markers 
and analysed by flow cytometry.  Fresh PBL were used as a control.  Initially, it was important to 
determine if trypsinisation cleaves the B cell marker, CD20.  Other markers were not analysed as 
previous experience had shown they were not trypsin sensitive.  Fresh PBL were incubated with 
trypsin for the same amount of time as in the channel and, post washing, were stained with the anti-
CD20 antibody (figure 7.9).  There was little, if any, effect of trypsin on the expression and detection 
of CD20+, indicating the marker is not sensitive to trypsin treatment and therefore anti-CD20 
antibody was used for subsequent B cell determinations. 
Due to time and reagent constraints, comparison of cells isolated from TNF-α and TNF+IFN treated 
endothelium only were conducted.  Cytokine treatment was shown to have an overall effect on 
which subsets of PBL were detected.  The fresh PBL were made up of approximately 65% T cells.  The 
PBL recruited during the flow assays were more varied in their number of T cells, with significantly 
less T cells recruited to TNF-α treated endothelium (figure 7.10).  This decrease is due to the less 
efficient binding of CD4+ T cells in the TNF-α treated endothelium, with only 20% of the PBL being 
CD4+, compared to 45% in the control.  Although in comparison to the control, the TNF+IFN 
condition also has less CD4+ cells present, this is not significant due to high experimental variation.  
CD8+ T cells have similar numbers within each condition, as do B cells and memory CD4+ T cells.  
However, the proportion of NK cells and memory CD8+ T cells within the populations isolated from 
the flow assay show small, consistent, but insignificant increases in comparison to the control (figure 
7.10). 
Using the fresh PBL control data, it was possible to determine if subsets of cells more readily 
adhered to the cell surface than others over the different cytokine treatments.  As with the total PBL 
fraction, less than 1% of the total number of cell type perfused adhered to the endothelial cell 
surface (figure 7.11).  Also similar was that the different cell subtypes adhered to TNF+IFN treated 
endothelia significantly better than endothelium treated with TNF-α alone (figure 7.11).  Although T 
cells make up the majority of those bound, the binding was very inefficient, at only 0.1 or 0.25% 
(TNF-α and TNF+IFN treated conditions, respectively).  This pattern was also true for CD4+ T cells, 
which has similar adhesion efficiencies to T cells.  Conversely, NK cells have a particularly high 
efficiency of adherence (0.35% for TNF-α and 0.6% for TNF+IFN), even though total numbers were 
low.  The memory subset of T cells also had very efficient binding in both cytokine treated 
conditions, however TNF-α stimulated endothelial cells bound significantly less memory CD8+ T cells 
than TNF+IFN (figure 7.11). 
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Figure 7.9 The effect on trypsin treatment on antibody binding of CD20, the B cell marker.   a) fresh 
PBL or b) fresh PBL incubated with trypsin were stained with anti-CD20 antibody with a PE-Cy7 
marker and analysed by flow cytometry. 
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Figure 7.10 Effect of cytokine treatment on adherence of different PBL subtypes to endothelium.  Fresh donor PBL or PBL isolated after perfusion onto TNF-
α or TNF+IFN treated endothelium were stained for various lymphocyte markers and analysed by flow cytometry.  Plotted as % within lymphocyte sample ± 
SEM, from 3 independent experiments. Overall, ANOVA showed that cytokine treatment has a significant effect on which subset of cells bind (p<0.05).  
*p<0.05 **p<0.01. 
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Figure 7.11 Effect of cytokine treatment on adherence on subtypes of PBL to the endothelial cell surface. Fresh donor PBL or PBL isolated after perfusion 
onto TNF-α or TNF+IFN treated endothelium were stained for various lymphocyte markers and analysed by flow cytometry.  Adhesion is determined by the % 
of the subtypes perfused, plotted ± SEM, from 3 independent experiments.  ANOVA shows significantly more of the cell subtypes adhered to TNF+IFN treated 
endothelial cells than TNF-α alone p<0.01.  Bonferroni analysis shows a significant difference between adherence of memory CD8+ between TNF and 
TNF+IFN (p<0.05).
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7.2.  The effect of blocking the chemokine receptors CXCR3 and CCR5 on PBL adherence 
PBL were incubated with neutralising antibody against CCR5 or CXCR3 before perfusion to determine 
the effect on adherence.  At both 2 and 16mins post PBL perfusion, there were no significant differences 
between the adherence of control PBL and those blocked for either CXCR3 or CCR5 (figure 7.12).  Within 
the TNF-α condition, it appears that addition of blocking antibody slightly improves the ability of PBL to 
adhere (figure 7.12a), however, stable adhesion of the PBL is ineffective as adherence is reduced in the 
blocked conditions by 16mins.  Conversely, in the TNF+IFN condition, adhesion is at 0.4% for all PBL 
fractions, and by 16mins only anti-CCR5 has retained this, with control and anti-CXCR3 reducing to 
0.35% adherence (figure 7.12b). 
As well as adherence to the endothelial surface, chemokines also have a role in transmigration – causing 
microvilli collapse and actin skeleton reorganisation.  Therefore the effect of blocking the chemokine 
receptors on PBL behaviour was also assessed (figure 7.13).  Comparison of control, untreated, PBL to 
those incubated with blocking antibody showed no significant difference for any of the PBL behaviours.   
It had previously been demonstrated than anti-CXCR3 antibody reduced PBL binding in TNF+IFN treated 
endothelium when cells were perfused at 0.1Pa(62).  Therefore, the flow rate was increased to 0.1Pa 
and the effect of blocking CXCR3 was examined (figure 7.14).  As expected, there was approximately half 
of adhereing cells at 0.1Pa than 0.05Pa (figure 7.14) however, there was still no effect on blocking 
CXCR3. 
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Figure 7.12 Effect of blocking chemokine receptors CXCR3 and CCR5 on PBL adhesion to endothelium.  
PBL were used fresh or incubated with either 10µg/ml of anti-CXCR3 antibody or 20µg/ml of anti-CCR5 
antibody for 15min before perfusion onto endothelium treated with a)TNF-α; b)TNF+IFN.  Adhesion was 
determined after either 2 or 16 min of washing.  Data are mean ± SEM from 2 independent experiments. 
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Figure 7.13 Effect of blocking the chemokine receptors CXCR3 and CCR5 on the behaviour of adhered 
PBL.  PBL were used fresh or incubated with either 10ng/ml of anti-CXCR3 antibody or 20ng/ml of anti-
CCR5 antibody for 15min before perfusion onto endothelium treated with either a)+b) TNF-α; 
c)+d)TNF+IFN.  PBL behaviour was assessed after a)+c) 2min; b)+d) 16min of washing.  Data are mean 
±SEM for 2 independent experiments. 
 Key:  
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Figure 7.14 Effect of shear rate and CXCR3 blockade on PBL adhesion to the endothelial surface.  PBL 
were used fresh or incubated with either 10µg/ml of anti-CXCR3 antibody  for 15min before perfusion at 
either 0.05Pa or 0.1Pa onto endothelium treated with TNF+IFN.  Data are mean ± SEM for 2 independent 
experiments (0.05Pa) a single experiment (0.1Pa). 
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Finally, to ensure that the blocking antibodies were efficiently binding to their chemokine receptor 
targets, fresh PBL were stained with either the unconjugated blocking antibody plus secondary, or a 
different, directly conjugated, antibody to CXCR3 or CCR5.  These were then subsequently analysed by 
flow cytometry (table 7.2 and figure 7.15).  Only 0.08% of cells were positive for CXCR3 when stained 
with unconjugated blocking antibody (figure 7.15c).  This was only 0.01% higher than the negative 
control of secondary antibody alone.  Using the directly conjugated CXCR3 antibody, 0.17% of cells were 
deemed to be positive for the chemokine receptor.  This value was low compared to data from a 
separate ongoing study within the lab, which has shown found 9% of cells stained positive for CXCR3 
when using a different conjugated antibody to the chemokine receptor.  It was determined that 2.06% 
of cells were positive for CCR5 when using the unconjugated blocking antibody, compared to 27.69% of 
cells staining positive with the directly conjugated antibody. However, some of this data may be false 
positive, as the staining was smeared within the negative as opposed to discrete positive and negative 
populations (figure 7.15f).  Nevertheless, this data is consistent with other studies using the same 
antibody, suggesting that the separation between positive and negative are accurate. 
7.3. PBL adhesion to HMEC-1 using flow and static based assays 
Above results examined PBL adherence to primary isolated HUVEC, however the immortal cell line 
HMEC-1 was also used if HUVEC were unavailable.  It was observed that very few PBL were captured 
from flow to TNF+IFN treated HMEC-1.  Moreover, after a couple of minutes the endothelial cells 
appeared to retract (figure 7.16).  It was therefore difficult to conduct any experiments of significance 
on this cell type under flow. 
 
 
 
 
 
 
 
93 
 
 
 
 
Table 7.2 Cell counts and percentage of PBL fraction which stained positive for chemokine receptors 
CXCR3 or CCR5.  PBL were incubated with either directly conjugated anti-CXCR3or anti-CCR5 antibodies, 
or with unconjugated blocking antibodies to CXCR3 and CCR5 with a conjugated secondary antibody.  
Positively stained cell numbers were then analysed by flow cytometry. 
 
 
 
 
Antibody Staining 
Number of cells positively 
stained 
% of PBL stained positive 
Secondary antibody only 14 0.07 
Unconjugated CXCR3 blocking 
antibody 
19 0.08 
Directly conjugated CXCR3 
antibody  
37 0.17 
Unconjugated CCR5 blocking 
antibody 
435 2.06 
Directly conjugated CCR5 
antibody 
6293 27.69 
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Figure 7.15 Flow cytometry analysis of fresh PBL stained for chemokine receptors CXCR3 and CCR5. 
Fresh PBL were analysed for chemokine receptor expression; a) unstained; b) only secondary antibody 
(FITC conjugated); c) blocking antibody to CXCR3 plus secondary antibody (FITC conjugated); d) anti-
CXCR3 FITC conjugated; e) blocking antibody to CCR5 plus secondary antibody (FITC conjugated); f) anti-
CCR5 APC conjugated. 
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Figure 7.16 Micrographs of HMEC-1 at 10 minute interval during a flow assay.  Single field captured a) 
8 minutes and b) 18 minutes after start of flow.  Endothelial cells appeared to “vibrate” during the assay, 
and circles emphasising areas where a change is apparent. 
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8. DISCUSSION 
 
In order to protect the host, leukocytes must exit the blood and enter into tissues, and they utilise 
various molecules to achieve this.  Many studies have used in vitro models to determine which, and 
how, various adhesion molecules, chemokines and cytokines affect lymphocyte recruitment to 
endothelium.  This study aimed to determine how the cytokines TNF-α and IFN-γ affect lymphocyte 
recruitment to endothelium, including which subsets of lymphocytes they preferentially bind, plus 
determine if the chemokine receptors CXCR3 and CCR5 are involved in this process. 
8.1. The effect of cytokines on lymphocyte recruitment and behaviour. 
HUVEC was treated with either TNF-α, IFN-γ or both and the effect on adhesion and transmigration of 
lymphocytes was observed.  Although insignificant, the use of both cytokines consistently caused the 
adhesion of more lymphocytes than the use of each cytokine individually.  Incubation of endothelium 
with various cytokines has previously been shown to bring about the expression of various molecules 
including P-selectin (47), VCAM-1 (52) and CXCL11 (69) (caused by TNF-α, IL-1 and IFN-γ respectively).  It 
is therefore plausible to suggest that the use of both cytokines together causes the expression of more 
proteins by the endothelium, thus enabling the recruitment of more, and different, lymphocytes.   This 
is supported with the flow cytometry data – TNF-α treated endothelium had recruited significantly less 
CD4+ T cells than the fresh PBL control, yet TNF+IFN treated endothelium did not.  Therefore, the 
addition of IFN-γ enables more efficient recruitment of CD4+ T cells.  It would be wise to repeat this 
experiment with IFN-γ treated endothelium to deduce if TNF+IFN treated endothelium binds more CD4+ 
T cells due to the cumulative effect of both cytokines, or IFN-γ itself allows for the more efficient 
recruitment.  As the relative numbers of memory CD4+ T cells remained constant, it could be proposed 
that this decrease is due to less efficient recruitment of naive CD4+ T cells to TNF-α treated endothelium.  
Previous studies have shown that transmigration of naive CD4+ T cells is reduced compared to CD8+ and 
memory CD4+ T cells (72).  It may therefore be possible that the lack of transmigration in those studies is 
due to the lack of recruitment of naive CD4+ T cells in the first place.   
The flow cytometry data shows proportions of each PBL subset within the fresh sample was, in the most 
part, consistent with those defined (78), including a 2:1 CD4+:CD8+ T cell proportion.  However, the 
amount of B lymphocytes within the fresh sample was low: consistently only 5% in this study, compared 
to what should be 10-15% (78).  This low detection is likely caused by the use of anti-CD20 antibody to 
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define B cells, even though it is not present on plasma cells (79).  It would therefore be appropriate to 
repeat the assay with the use of, for example, anti-CD38 and anti-CD138 antibodies, which are highly 
expressed on plasma cells (80).   
Although in comparison to T cells there were low number of NK cells bound to the cytokine treated 
endothelium, it actually had a very high efficiency of adhesion to both the TNF-α and TNF+IFN 
stimulated endothelium.  P-selectin has been shown to aid in the recruitment of lymphocytes to 
endothelium and its expression is upregulated by pre-treatment of the endothelium with TNF-α (47).  As 
this molecule has also been shown to bind NK cells (81) it may be that this efficient binding of NK cells, 
particularly in the TNF-α treated endothelium, is due to the upregulation of P-selectin by the endothelial 
cells. 
In this study, it was found that treatment of HUVEC stimulated with IFN-γ caused a significant increase in 
the amount of transmigration in comparison to stimulation with TNF-α.  The role of chemokines in 
transmigration is well established, and their roles are summarised in two reviews (57, 82).  A study by 
Mohan and colleagues has previously shown that different chemokines are produced by endothelium 
upon stimulation by different cytokine,s and that this had an effect on T cell transmigration (69).  It is 
therefore plausible that IFN-γ treated HUVEC produced chemokines more suited to PBL transmigration 
than the TNF-α treated endothelium.  Reduced recruitment, as well as transmigration, in the TNF-α 
stimulated HUVEC may also be explained by this production of different chemokines, due to role of 
chemokines in stable adhesion of lymphocytes (53, 60-62).   
In a recent study by McGettrick and colleagues, cells took on what appeared to be a “frustrated” 
phenotype, by transmigrating in and out of the endothelial cell monolayer multiple times (46).  This 
phenomenon was also observed here, in all three cytokine treated conditions. It was proposed that 
these frustrated cells would eventual leave the circulation after a longer time frame, due to not 
receiving additional signals for their retention and subsequent migration into compromised tissue.  
Within this study, the frustrated cells do not appear to leave the endothelium after 1 hour, as similar 
numbers of cells were seen at this time point in a single field.  However it is unclear whether the single 
field is representative of the entire channel, and thus whether over time the amount of PBL actually do 
decrease.  It is also of note that this single experiment only recorded PBL behaviour over 1 hour, so a 
longer wash period should also be conducted to determine if “frustrated” cells eventually exit the 
system altogether.  Over the 1 hour of washing, only 2 of the 33 originally bound PBL remained 
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stationary and phase bright.  This suggests that some PBL are predisposed not to transmigrate, but 
remain on the endothelial cell surface.  It would be interesting to observe if these cells are from a 
particular subset of the PBL, and isolating the individual cell types (T cells, B cells, NK cells) and running 
the flow assay individually would aid determination of this. 
8.2 The effect of blocking two chemokine receptors on lymphocyte recruitment.  
In this study, blocking of the chemokine receptors CXCR3 and CCR5 had no effect on lymphocyte 
recruitment.  This was of particular surprise for CXCR3, as previous results from McGettrick et al shows a 
75% decrease in lymphocyte recruitment when TNF+IFN treated endothelium is perfused with PBL 
treated with blocking antibody to CXCR3 (62).  This is not the only published data which has shown 
reduction when blocking CXCR3, with Piali et al and Curbishley et al also observing this (53, 61).  One 
possible explanation between the differences between this and the McGettrick study are the difference 
in shear flow rate, 0.05Pa here compared to 0.1Pa in the other study (62).  The 0.1Pa shear flow rate 
was also used by Piali and colleagues to monitor lymphocyte recruitment to HUVEC (61).  Although 
Curbishley et al. conducted their experiments at 0.05Pa (53), their study involved specialised liver 
activated T cells and liver endothelium, and so was not the same model as used in this study. 
Nonetheless, the blocking of CXCR3 on PBL still had no effect on lymphocyte recruitment at 0.1Pa, and 
therefore an alternative explanation was required. 
Further research into the assays showed that the new antibody ordered for this study was a different 
clone to that used in published data, so it was suggested that this could explain the inconsistent results.  
Therefore flow cytometry analysis was used to ensure efficient binding of the new antibody to the PBL.  
The blocking antibody stained fewer cells in comparison to the fluorescently conjugated antibody, which 
could suggest that the blocking antibody had not bound.  However, it is unlikely that the antibody 
cannot bind, because not only have two papers shown that it is able to detect CXCR3 expression on mast 
cells and melanomas (83-84), a 2010 paper by Oo and colleagues used the same antibody clone to 
inhibit Treg binding in shear flow rates of 0.05Pa (85).   
CXCR3 has two isoforms, A and B.  Lasagni et al successfully utilised the blocking antibody clone to 
detect the CXCR3-B isoform in transfectants (86), and so it is plausible that only this isoform is bound by 
the antibody.  A way to examine if this is the case would be to form both CXCR3-A and CXCR3-B 
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transfectant cell lines and using both the blocking antibody, and a secondary, to detect if the cell lines 
stain positive via ELISA. 
Another explanation of the differing results between this and previous studies is that the blocking 
antibodies used prevent different interactions between CXCR3 and its ligands.  The antibody clone used 
in the three studies mentioned (53, 61-62) has been shown to block CXCL10, but not CXCL9 binding to 
CXCR3 (87), whereas the antibody clone used within this study was shown to neutralise CXCL11 
mediated chemotaxis.  It is therefore possible that the two different antibodies used block slightly 
different ligand-CXCR3 interactions, thus causing different results between this study and published 
data.  To assess if this is the case, a calcium flux assay could be conducted using all three chemokines, 
aster blocking of PBL with the anti-CXCR3 antibody, and thus detecting if the cell is activated or not.  If 
this is found to be the case, it would imply that CXCL11 does not have a role in T-cell recruitment to 
cytokine treated endothelium, and only a role in transmigration of PBL (69). 
8.3 The use of HMEC-1 in flow.  
The previously described assays all utilised primary HUVEC, however, when unavailable the 
immortalised HMEC-1 cell line was used.  Upon applying flow conditions, it was noted that few PBL 
bound to the surface (0.15% adhesion compared with 0.55% when HUVEC used – data not shown (n=1)).  
It is likely that this less efficient binding was due to the HMEC-1 not surviving the flow process – the 
endothelium “vibrated”, and often pulled away from the slide surface.  This would imply that HMEC-1 
cannot be used in flow assay conditions – however Grubb et al utilised the cell line in a glass slide within 
a parallel plate flow chamber at shear stress values 0.025-0.4Pa (88). As the shear stress used in these 
experiments, 0.05Pa, is within this range, the HMEC-1 should have been able to withstand the flow.   
It is therefore possible that the problems with the use of HMEC-1 under flow are the original seeding 
density or the use of Ibidi slides.  The latter are a channel with two wells containing media on either end 
(figure 6.1), and so it is possible that the fresh media in the wells at either end does not reach the 
HMEC-1 located in the centre of the channel.  However, this is unlikely as the HUVEC were not affected 
by growth within the Ibidi slide.  To ensure that the Ibidi slide does not affect the use of HMEC-1 within 
a flow assay, it would be wise to conduct an experiment in which fresh complete media is constantly 
circulated through the slide to ensure the cells have access to the nutrients they require. 
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8.4 Future work.  
First and foremost, tests must be conducted to ensure the blocking antibodies function correctly.  This 
could be conducted in various ways, for example chemotaxis assays or calcium flux assay.  This is 
paramount to ensure the differences between the data here and that found previously within the 
laboratory are genuine. 
Second, more accurate data on the effect of time on lymphocyte adhesion must be found.  This study 
conducted a single assay for 1 hour, and this was only in a one field, therefore its representation for the 
whole slide can be questioned.  Further analysis would include researching 10 fields down the slide at 
different time points, and this would include conducting the experiment for longer than 1 hour. 
Although the cell subtypes which bound to the endothelium here were found for TNF-α and TNF+IFN, 
this was not conducted for the IFN-γ condition alone.  As transmigration is highest in the IFN-γ treated 
condition, it would be interesting to see if a difference is cellular recruitment may account for this. 
Fourthly, although the different subtypes of PBL bound to the endothelium, it was not distinguished 
whether different subtypes of cells preferentially transmigrated through the endothelium.  The subsets 
of transmigrated cells has been the focus of many studies (65, 69, 72-73), however these studies have 
used isolated T cells, as opposed to PBL as a whole.  To determine, phase bright cells and phase dark 
cells should be retrieved from the slides separately, and their differences deduced.  It may be possible to 
do this by flowing EDTA through the channel to loosen the phase bright cells, before trypsin treatment 
to retrieve the remaining, transmigrated, cells. 
Finally, determination of the optimal seeding density of HMEC-1 is paramount before more assays are to 
be conducted.  It would then be possible to determine if the Ibidi slide has an effect on the use of HMEC-
1 within a flow system.  
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APPENDIX A:  Information on CCRL2 gene and primer locations. 
 
CCRL2 gene sequence Part 1: Current known Introns and exons.  Exons marked with a grey background 
 
CTACTGGGGGAGGAGAGACCTTATTAGGAAGTGCCTCCGTTCTGGGTTCTCCCTGCTCCAGGGTGAGTTTCATTTTCTGTCCTAGCTTCCAGGATGCTCGGGGCTTAATGTTCACTCATGTTT
ATCTGGGCTCTTTTCTTTCTGTTTTCTTATTGGTCTCTTCATTACCTATTTCTGTTTTTATAGTTACACTTTCCGTTTCACATGCTGATAATGCAAAGGATGTGCCTAAATCACAGACATCACCTA
GTCCCCAGATTAGGTCAGCCATAGCTACACAGAGTCGTGGGCCTGAGGGCAGTTTACACATGCTTCCCGCCCCTCCCCCCCAACTCTTTGAAGTTCTTCTTCTTCTTCTTGAAATACCCATCTTT
AACCAGCATCCTTCTCCTCCCGCCCACTCCCTTCCACTCCAAGACCAGGCAACTGTCCAATTCCTTTCTTCATCCCCATTCTCCATTGGAAACCAAGTCTCCCCTCCTCACAGTCCACCTGACCGT
GTCCCACACGTCCTCACACAGGACTTTCCCCCGGGGCTTCCCCTGAGCGGGGTCAGCTACATCAAGTGTCCCAGCATCAACTGCTTCCTTCCAGCTGCTTGCAACACTCTTTGCTTTCTGACG
TAGGAATGCTCACACCAGACTTGCATTTAGCAGCGCTCCTTTTCTGTCCAGCTCTGTCCCCAACCTCCTTCCCGACTGATACCACTTGCTTCCATGTTCTCTGGTGAGTATGGACACGTTTGT
ACTCTGGAAACTGTTATCTACTCAGGGAACTTATGTCAGAAGCCAGGGGGTGGGGTGGTGCGTCTCGGCTTCTGACATCACACTCTGATTATCACTGGAAGCAGGCGTGGGTTAGTGTCCT
TATCCGAGGCAGCCTGGAGGACAGCTGGCTAAGAGGTACAGAGAAGTCAAACTTGGGATACCGGGAGAGGGAGAGATGAAAACAACTTCTCAATTTCTCTGCGGCTGACAGAAGCTC
CTGAGAGAGGCTTTCAGAACTTGATTCCAGCTGGCCCGTGAAAGCTGTGTCTGGACGGGAGAGCCTCAGAGGAATAAACAGTGCCTTCTCTGGCTTCTCCGGGTCATGACCAGTCTGTTC
AGAAGGAAGTGGTGTTTCTCTGACCCCACTGTTCCCACAGCCCCCTGGATGGTAGATCATGGGGCTGCACCCTTCCCCACCCTTGGGAACTCAGTCAAACGGTTATCTTTATCTCGCCAGC
TTGTCCTCGTGCTTGACCAGCGCAGTTTCACTTTTGCAAACATCTGTTTATATCCCTTGAGAGAAAAAATATCAAGCAACCTGCCTCAAACGACGCTGTTTTGTCCGGTGAGCAAGGTAAG
AAACTGTTTTAAACATCTGGGAAGTAGGCGGGCACCAACTTCTGAAGCTTAAGCCAGTCTCTGGTTGTTTTTAACTCTTTGTTTTCTTAGATCCTATCTCCCACGTAGAGTCTCGTTTCAACCA
AAGAACTTAAGTGGCTTTAACGTCCCTGACTCTTTCTGTACCAGGCAGTTTCTGTCACATTAGCAGCGTGGTCCCTGGGTGCTTAATGAGGAGATTTGAGTACGGCCGCCCACGCTGGGGTG
GGGGGTGGGGGCATAGTTACTTTCAGTCTTTGGCTGTCGGATGGAGGGGAATCATGACCTCTGGTTTCCCCACAGGACAGCCTCCGATGGATAACTACACAGTGGCCCCGGACGATGAAT
ATGATGTCCTAATCTTAGACGACTACCTGGACAACAGTGGGCCGGACCAAGTTCCGGCCCCCGAGTTCCTCTCCCCCCAGCAGGTGCTGCAGTTCTGCTGCGCGGTGTTTGCGGTGGGTC
TCTTGGACAACGTGCTGGCGGTGTTTATCTTGGTGAAATACAAAGGACTCAAGAATCTGGGGAACATCTACTTCCTAAACCTGGCACTTTCAAACCTGTGTTTCCTGCTTCCCCTGCCGTTC
TGGGCCCATACTGCAGCACACGGGGAAAGCCCTGGCAATGGGACCTGTAAAGTTCTTGTCGGACTCCACTCCTCGGGCTTATACAGCGAGGTGTTTTCCAACATCCTCCTCCTTGTGCAA
GGATACAGGGTGTTTTCCCAAGGGCGACTGGCCTCCATCTTCACGACAGTGTCTTGTGGTATTGTTGCGTGCATCCTGGCATGGGCCATGGCTACTGCGCTCTCTTTGCCCGAGTCTGTGT
TTTATGAGCCTCGGATGGAAAGACAGAAACACAAGTGTGCCTTTGGCAAACCTCACTTCTTGCCAATCGAAGCGCCGCTCTGGAAGTACGTTCTGACGTCAAAAATGATCATCTTGGTAC
TTGCTTTTCCTCTGCTGGTTTTTATAATCTGCTGCAGGCAACTGAGGAGAAGGCAGAGCTTCAGGGAGAGACAGTACGACCTCCACAAGCCGGCTCTTGTCATAACGGGCGTGTTCCTTT
TGATGTGGGCGCCTTACAACACTGTGCTTTTCCTGTCTGCTTTCCAGGAACACTTGTCCCTGCAGGATGAGAAGAGCAGCTACCACCTGGACGCAAGTGTTCAGGTCACACAGCTGGTAG
CGACCACCCACTGCTGCGTCAACCCGCTGCTCTATTTGCTTCTTGACCGGAAGGCCTTTATGAGATACCTTCGCAGCCTGTTCCCACGGTGCAATGATATCCCCTATCAAAGTAGTGGAGG
CTATCAGCAAGCGCCTCCAAGGGAAGGTCATGGCAGGCCCATTGAACTGTACAGCAATTTGCATCAAAGGCAGGATATAATATAATATAAACACTCAACCTTGTCTCTTCACATTGTTTT
ATGCCATTTTTATATGTTTGTATAAAAATAGAATATAAGAGGAAAGGGGGCTGGTTAATGAACATTTACTACTAAGCGTTGAATTTGTCTCTGGCACACGGTTAAGTTATTTATAAAGGT
GAATTCCACTCTTCCTCTTTAGCGTTTGTCCGCAGTGTGGGCGTGGGCGGTGTGCATTCCATAAACTGAAGCTCGGTAGTTGTCCAAAGTTACATAACTATAAAGTGGCAAAACTGATGT
GTAAACTCAGAGATCACTGGCCCCAGAGTCTGTGAGTTATCCAAGCGTGCCAGCCTTTCAGTAACTGTCAGCTAGCAGTGGTGGCATGTCTGTCATCCCAGCACTCTAGGAGGCGGAGG
CAGGAGGCATCTCACAAATGCAAGTATAACCTGACTTCCCCCAACCTCAATTCTTTTTTTTTTGTTGTTGTTGTTGTTCATCAAAATACATGCAATAAATATATATATTTTTAAAGCACATCT
TGAAGGTTGGGATTATAGTTTTGTTGGTAGAACATTAGCCCCCCAAGCCCAGCTTTGATCTATAGCATGGCATCTACCTAGTATGATCATGCCCATTTTGTTTTGTTTTGGGAGGCAGGGTTT
CTCTGTGTAGCCCTGGCTGTCCAAGAACTCTCTTTGTAGTCGAGGCTAGCCTTGAACTCAGAGATGTGCCTGCCTCTGTTTCCTGAGTGCTAACACCTGGTGATGCCCATCTCAATATCAGCTC
AACTCAAGAGGTGGACACAGAAAGATGAGAAGTTCAAGGTCATTCTTGGCTGTAGAGTTAGTTCAAGGTCACCTGGATCCATTAGACCCTGTCTTTAAAAAAAAAAAAAAAAACCCTAAGC
CCAAATTGACCAAATTCTAAGTTAGAAGCAAGTGTTGGCTCATGTTCCTGCAGGCCCTGAGAGGTGCTGGCTGCGTGGTAGCGGTGCAAGCCAATGGCAAGGTCTGGTGGAACCTGCTGG
GCTCTCTTGACTACTCACTATACTCAGGTTTGTCTGATTCTTCCAGCCCTTGAGTCCTCCGAGGTTTCAGAGTCTGTATTATGAAGGCTCTGTGTCTTAGGAAAGT 
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Table A1.  Designed PCR primer sequences and in which experiment used. 
 
Primer Sequence Experiment 
CCRL2 long variant forward TCCCTGGGTGCTTAATGAGG Taqman RT-PCR 
CCRL2 long variant reverse ACCTATTGATGTGTCACCGGG  Taqman RT-PCR 
CCRL2 long variant probe AGATTTGAGTACGGCCGCCCACG Taqman RT-PCR 
CCRL2 short varaint forward GTCCGGTGAGCAAGGACAG Taqman RT-PCR 
CCRL2 short variant reverse CTGATGGACCTGTTGTCACCC Taqman RT-PCR 
CCRL2 short variant probe TCCGATGGATAACTACACAGTGGCC Taqman RT-PCR 
CCRL2 forward CCTGCCTCAAACGACGCTGTTTTGT SYBR Green RT-PCR 
CCRL2 reverse ATCATATTCATCGTCCGGGGCCACT SYBR Green RT-PCR 
CCRL2 forward HindIII TTTTAAGCTTGGGAATTCGTCGACTGGATCCGGTAC Cloning 
CCRL2 forward HindIII ATG TTTTAAGCTTCATGGATAACTACACAGTGGC   Cloning 
CCRL2 reverse SalI TTTTGTCGACTTATATTATATCCTGCCTTTGATGC Cloning 
β2-Microglobulin forward CATACGCCTGCAGAGTTAAGCA Taqman RT-PCR 
β2-Microglobulin reverse ATCACATGTCTCGATCCCAGTAGA Taqman RT-PCR 
β2-Microglobulin probe CAGTATGGCCGAGCCCAAGACCG Taqman RT-PCR 
β-actin forward CGTGAAAAGATGACCCAGATCA Taqman RT-PCR 
β-actin reverse TGGTACGACCAGAGGCATACAG Taqman RT-PCR 
β-actin probe TCAACACCCCAGCCATGTACGTAGCC Taqman RT-PCR 
IRF-4 forward GGAGGACGCTGCCCTCTT Taqman RT-PCR 
IRF-4 reverse TCTGGCTTGTCGATCCCTTCT Taqman RT-PCR 
IRF-4 probe AGGCTTGGGCATTGTTTAAAGGCAAGTTC Taqman RT-PCR 
CXCR5 forward GCTCTGCACAAGATCAATTTCTACTG Taqman RT-PCR 
CXCR5 reverse CCGTGCAGGTGATGTGGAT Taqman RT-PCR 
CXCR5 probe CCATCGTCCATGCTGTTCACGCC Taqman RT-PCR 
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Table A2.  Primers ordered direct from Applied Biosystems: Taqman Gene Expression Assay. 
 
Primer ID Number 
CCR1 Mm00432606_s1 
CCR2 Mm99999051_gH 
CCR4 Mm00438271_m1 
CCR5 Mm01216171_m1 
CCR7 Mm00432608_m1 
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CCRL2 gene sequence Part 2: Location of Taqman long CCRL2 primers/probe 
 
Exons 2 and 3 and intron 3. 
 
………ATCACTGGAAGCAGGCGTGGGTTAGTGTCCTTATCCGAGGCAGCCTGGAGGACAGCTGGCTAAGAGGTACAGAGAAGTCAAACTTGGGATACCGGGAGAGGGAGAGATG
AAAACAACTTCTCAATTTCTCTGCGGCTGACAGAAGCTCCTGAGAGAGGCTTTCAGAACTTGATTCCAGCTGGCCCGTGAAAGCTGTGTCTGGACGGGAGAGCCTCAGAGGAATA
AACAGTGCCTTCTCTGGCTTCTCCGGGTCATGACCAGTCTGTTCAGAAGGAAGTGGTGTTTCTCTGACCCCACTGTTCCCACAGCCCCCTGGATGGTAGATCATGGGGCTGCACCCT
TCCCCACCCTTGGGAACTCAGTCAAACGGTTATCTTTATCTCGCCAGCTTGTCCTCGTGCTTGACCAGCGCAGTTTCACTTTTGCAAACATCTGTTTATATCCCTTGAGAGAAAAAAT
ATCAAGCAACCTGCCTCAAACGACGCTGTTTTGTCCGGTGAGCAAGGTAAGAAACTGTTTTAAACATCTGGGAAGTAGGCGGGCACCAACTTCTGAAGCTTAAGCCAGTCTCTGG
TTGTTTTTAACTCTTTGTTTTCTTAGATCCTATCTCCCACGTAGAGTCTCGTTTCAACCAAAGAACTTAAGTGGCTTTAACGTCCCTGACTCTTTCTGTACCAGGCAGTTTCTGTCACAT
TAGCAGCGTGGTCCCTGGGTGCTTAATGAGGAGATTTGAGTACGGCCGCCCACGCTGGGGTGGGGGGTGGGGGCATAGTTACTTTCAGTCTTTGGCTGTCGGATG
GAGGGGAATCATGACCTCTGGTTTCCCCACAGGACAGCCTCCGATGGATAACTACACAGTGGCCCCGGACGATGAATATGATGTCCTAATCTTAGACGACTACCTGGACAA
CAGTGGGCCGGACCAAGTTCCGGCCCCCGAGTTCCTCTCCCCCCAGCAGGTGCTGCAGTTCTGCTGCGCGGTGTTTGCGGTGGGTCTCTTGGACAACGTGCTGGCGGTGTTTATCT
TGGTGAAATACAAAGGACTCAAGAATCTGGGGAACATCTACTTCCTAAACCTGGCACTTTCAAACCTGTGTTTCCTGCTTCCCCTGCCGTTCTGGGCCCATACTGCAGCACACGGG
GAAAGCCCTGGCAATGG......... 
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CCRL2 gene sequence Part 3: Location of Taqman short CCRL2 primers/probe 
 
Exons 2 and 3 and intron 3.  The forward primer does not span the intron, but does span the exon2-exon3 joining region. 
 
 
………..ATCACTGGAAGCAGGCGTGGGTTAGTGTCCTTATCCGAGGCAGCCTGGAGGACAGCTGGCTAAGAGGTACAGAGAAGTCAAACTTGGGATACCGGGAGAGGGAGAGAT
GAAAACAACTTCTCAATTTCTCTGCGGCTGACAGAAGCTCCTGAGAGAGGCTTTCAGAACTTGATTCCAGCTGGCCCGTGAAAGCTGTGTCTGGACGGGAGAGCCTCAGAGGAAT
AAACAGTGCCTTCTCTGGCTTCTCCGGGTCATGACCAGTCTGTTCAGAAGGAAGTGGTGTTTCTCTGACCCCACTGTTCCCACAGCCCCCTGGATGGTAGATCATGGGGCTGCACC
CTTCCCCACCCTTGGGAACTCAGTCAAACGGTTATCTTTATCTCGCCAGCTTGTCCTCGTGCTTGACCAGCGCAGTTTCACTTTTGCAAACATCTGTTTATATCCCTTGAGAGAAAAA
ATATCAAGCAACCTGCCTCAAACGACGCTGTTTTGTCCGGTGAGCAAG……..GACAGCCTCCGATGGATAACTACACAGTGGCCCCGGACGATGAATATGATGTCC
TAATCTTAGACGACTACCTGGACAACAGTGGGCCGGACCAAGTTCCGGCCCCCGAGTTCCTCTCCCCCCAGCAGGTGCTGCAGTTCTGCTGCGCGGTGTTTGCGGTGGGTC
TCTTGGACAACGTGCTGGCGGTGTTTATCTTGGTGAAATACAAAGGACTCAAGAATCTGGGGAACATCTACTTCCTAAACCTGGCACTTTCAAACCTGTGTTTCCTGCTTCCCCTGC
CGTTCTGGGCCCATACTGCAGCACACGGGGAAAGCCCTGGCAATGG......... 
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CCRL2 gene sequence Part 4: Location of SYBR Green forward and reverse primers 
 
Exons 2 and 3 and intron 3. 
 
 
………ATCACTGGAAGCAGGCGTGGGTTAGTGTCCTTATCCGAGGCAGCCTGGAGGACAGCTGGCTAAGAGGTACAGAGAAGTCAAACTTGGGATACCGGGAGAGGGAGAGATG
AAAACAACTTCTCAATTTCTCTGCGGCTGACAGAAGCTCCTGAGAGAGGCTTTCAGAACTTGATTCCAGCTGGCCCGTGAAAGCTGTGTCTGGACGGGAGAGCCTCAGAGGAATA
AACAGTGCCTTCTCTGGCTTCTCCGGGTCATGACCAGTCTGTTCAGAAGGAAGTGGTGTTTCTCTGACCCCACTGTTCCCACAGCCCCCTGGATGGTAGATCATGGGGCTGCACCCT
TCCCCACCCTTGGGAACTCAGTCAAACGGTTATCTTTATCTCGCCAGCTTGTCCTCGTGCTTGACCAGCGCAGTTTCACTTTTGCAAACATCTGTTTATATCCCTTGAGAGAAAAAAT
ATCAAGCAACCTGCCTCAAACGACGCTGTTTTGTCCGGTGAGCAAGGTAAGAAACTGTTTTAAACATCTGGGAAGTAGGCGGGCACCAACTTCTGAAGCTTAAGCCAGTC
TCTGGTTGTTTTTAACTCTTTGTTTTCTTAGATCCTATCTCCCACGTAGAGTCTCGTTTCAACCAAAGAACTTAAGTGGCTTTAACGTCCCTGACTCTTTCTGTACCAGGCAGTTTCTGT
CACATTAGCAGCGTGGTCCCTGGGTGCTTAATGAGGAGATTTGAGTACGGCCGCCCACGCTGGGGTGGGGGGTGGGGGCATAGTTACTTTCAGTCTTTGGCTGTCGGATGGAGG
GGAATCATGACCTCTGGTTTCCCCACAGGACAGCCTCCGATGGATAACTACACAGTGGCCCCGGACGATGAATATGATGTCCTAATCTTAGACGACTAC.......... 
 
 
APPENDIX B: Vector pLNCX2 information. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B1.  Vector pLNCX2.  Vector cut with restriction enzymes HindIII and SalI (red lines) for insertion of 
CCRL2 DNA, and subsequently at the SalI and XhoI (green line) sites for confirmation that the DNA had been 
inserted.  Sequencing used forward and reverse primers (black and clear arrows) to ensure CCRL2 DNA insert 
had not any base pair changes during the transformation process.  Ampicillin resistance enabled bacteria 
which had taken up the plasmid to grow on agar plates containing carbenicillin. 
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APPENDIX C: NCBI Blast2 sequence analysis of clones positive for CCRL2 insert according to 1% agarose 
gel analysis. 
Insert sequence for HindIII amplified CCRL2.  Forward primer for plasmid. 
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Insert sequence for HindIII amplified CCRL2 DNA.  Reverse primer for plasmid. 
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Insert sequence for HindIII-ATG amplified CCRL2.  Forward primer for plasmid. 
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Insert sequence for HindIII amplified CCRL2.  Reverse primer for plasmid. 
 
 
 
 
 
 
 
